Targeting fibrosis, mechanisms and cilinical trials.

Introduction

Fibrosis is an important cause of global morbidity and mortality. Common diseases associated with fibrosis include hepatitis virus, nonalcoholic fatty liver disease (NAFLD), chronic kidney diseases, idiopathic pulmonary fibrosis (IPF), pneumonconiosis, and cystic fibrosis. The annual combined incidence of major fibrosis-related diseases is approximately 4968 per 100,000 person-years, causing huge disease burden 1 . Fibrosis-related diseases accounted for a large proportion of global disability-adjusted life-years (DALYs) in 2019 2 . Therefore, fibrosis is increasingly recognized as a major health challenge.

The normal wound healing process and the pathogenesis of fibrotic diseases share many mechanisms in common 3 . Various factors, such as infectious agents, alcohol, environmental particles, and gene mutation, can cause damage to normal tissue structures, triggering a wound-healing response 4 . The tissue repair response often starts with inflammation. Activated inflammation contributes to the upregulation of inflammatory mediators and promotes the migration of neutrophils, eosinophils, and macrophages to the injured site to clear debris and necrotic areas. Fibroblasts and other mesenchymel cells are then thansformed to myofibroblasts via the upregulation of fibrotic cytokines such as fibroblast growth factors (FGFs) and platelet-derived growth factor (PDGFs), which secrete extracellular matrix (ECM) components 5 . In normal wound healing response, activated myofibroblasts would be cleared from wound site via apoptosis after injury repair 6 , 7 . However, in fibrotic process, myofibroblasts fail to undergo apoptosis and are continuously activated, eventually leading to excessive ECM deposition 8 . The progressive accumulation of ECM leads to increased stiffness of injured tissue and hinders oxygen diffusion 9 , and further promotes cell damage. In addition, dysfunction of other parenchymal cells and dysregulated cell-cell interaction caused by injury are also the important causes of fibrosis, such as vascular proliferation induced by abnormal function of vascular endothelial cells 10 . The fibrotic process can occur in many organs, with fibrosis of liver, lung, kidney, and heart accounting for a large proportion of all fibrotic diseases 1 , 11 . The different characteristics of tissue structure and microenvironment between these organs lead to differences in the fibrotic process (Fig. 1 ). Despite increasing in-depth research on fibrosis, the mechanisms have not been fully explained, thus hindering the advancement of targeted drug research for fibrosis. Fig. 1 The aetiology of fibrosis in different tissues or organs

In this review, we briefly introduce the aetiology and epidemiology of several fibrosis-related diseases, including liver fibrosis, renal fibrosis, heart fibrosis, lung fibrosis, cystic fibrosis, and myelofibrosis. We then focus on the abnormal cells, aberrant signaling pathways, and anti-fibrotic drugs in fibrosis, providing reference for the mechanism and drugs research of fibrosis.

Aetiology and epidemiology

Liver fibrosis

Liver fibrosis, as a pathophysiological result of chronic liver injury, is the leading cause of mortality from chronic liver diseases (CLDs) worldwide. CLDs mainly include chronic infection with hepatitis virus, NAFLD, alcoholic liver diseases, and autoimmune liver diseases 12 , 13 . CLDs could progress to advanced liver fibrosis and eventually to cirrhosis 14 , which is the 11th cause of global death 15 . Hepatitis B virus (HBV), hepatitis C virus (HCV), and alcohol are the most common causes of DALYs from cirrhosis 16 . Alcoholic-related liver cirrhosis and other chronic liver diseases resulted in 332,300 all-age deaths and 9,785,400 years of life lost (YLLs) in 2017 17 . The prevalence of NAFLD is around 25% worldwide 18 , and its advance can progress to nonalcoholic steatohepatitis (NASH) 19 . NASH-related cirrhosis caused 118,000 all-age deaths and 3,285,500 YLLs in 2017 17 .

Renal fibrosis

Renal fibrosis is caused by the damage to normal renal tubules, which eventually leads to glomerulosclerosis, tubulointerstitial fibrosis, and angiosclerosis 20 . Renal fibrosis is not a direct clinical diagnosis but a progressive and irreversible pathological feature of all chronic kidney diseases (CKDs) 21 , 22 . In 2017, CKDs caused 35.8 million DALYs, nearly a third of which were diabetic nephropathy 23 .

Cardiac fibrosis

Cardiac fibrosis manifests as either reactive interstitial fibrosis and replacement fibrosis 24 . Reactive interstitial fibrosis refers to the expansion of interstitial and perivascular spaces without significant loss of cardiomyocytes and fundamental changes in muscle bundle structure 25 . Replacement fibrosis replaces dead cardiomyocytes with extracellular matrix tissue and fibroblasts, disrupting the continuous pattern of muscle bundles but maintaining tissue integrity 26 . Replacement fibrosis mainly occurs in response to ischaemia, ischaemia/reperfusion, inflammation, and toxic injury. Cardiac fibrosis is a common pathophysiological manifestation of most cardiovascular diseases, which are the leading cause of death, morbidity, and disability in most contries 27 , 28 .

Lung fibrosis

The causes of chronic respiratory diseases are varied, including allergens, chemicals, radiation, microbial agents, and environmental particles 29 . Lung fibrosis is the main clinical outcome of most chronic respiratory diseases, such as pneumoconiosis and IPF 30 . IPF is the most common interstitial lung fibrosis with unknown aetiology 31 , 32 . The prevalence of IPF varies widely across regions, ranging from 0.33 to 2.51 in Europe, 0.57 to 4.51 in Asia-Pacific countries, and 2.40 to 2.98 in North America 33 . IPF mainly occurs in elderly individuals, with high mortality and morbidity 34 , 35 . Pneumoconiosis is a major occupational diseases caused by the prolonged inhalation of inorganic particles at work 36 – 38 . In 2017, all-age deaths of pneumoconiosis was 21,600 and 426,900 YLLs 17 .

Cystic fibrosis

Cystic fibrosis is an autosomal recessive disorder mainly caused by mutations in the cystic fibrosis transmembrane conductance regulatory protein (CFTR) gene 39 . Compared with the high incidence rate of cystic fibrosis in Caucasians, cystic fibrosis was much less common in Asia, and the incidence rate varied from 1:10,000 to 1:40,750 among countries 40 – 42 .

Myelofibrosis

Myelofibrosis, a myeloproliferative tumour with collagen deposition in bone marrow and splenomegaly, has low morbidity and shortened life expectancy 43 – 45 . Aberrant activity of the Janus kinase (JAK) /signal transducer and activator of transcription (STAT) pathway contributes to myelofibrosis 43 , 46 .

Abnormal cells involved in fibrosis

Fibrosis is the result of the interaction between a variety of cells. Cell maps of fibrosis such as IPF, liver fibrosis, renal fibrosis, and systemic sclerosis have been well studied via single-cell sequencing 47 – 50 . These studies confirmed the key role of epithelial cells, endotheliocytes, immunocytes, and fibroblasts in fibrosis, and identified some new cell types involved in the pathological progress. This section will review the major cell types in fibrotic diseases.

Epithelial cells

Epithelial cells, including basal cells, secretory cells, club cells, ciliated cells, and goblet cells, are essential cells to maintain tissue homeostasis in many organs 51 . In fibrotic process, chronic injury resulted in the apoptosis of epithelial cells, thus destroying the epithelial structure, promoting dysfunctional repair and pathogenic activation of fibroblasts 52 . Moreover, the epithelial-mesenchymal transition (EMT) is recognized as an important source of myofibroblasts. EMT under pathological conditions can lead to the reduction of normal epithelial cells, destroy the normal structure of the tissue, and promote the production of collagen fibers 53 .

Studies have showed that epithelial cells, such as alveolar epithelial cells, goblet cells, ciliated cells, and club cells, are crucial for the development of lung fibrosis 54 , 55 . Alveolar epithelial cells, including alveolar type 1 epithelial (AT1) and AT2 cells, are one of the main epithelial cells in lung tissue and maintain the integrity of the alveolar wall. When the injury leads to the death of AT1 cells, AT2 cells proliferate and differentiate into AT1 cells, so that the normal structural of the alveoli is maintained 56 . A new epithelial cell subset Axin2 + AT2 cells with both progenitor and epithelial properties was found in lung and regulate alveolar regeneration 57 , 58 . AT2-transdifferentiated plastic keratin 5 basal cells were co-located with pathological transforming growth factor (TGF) -β1 hi collagen triple helix repeat containing 1 (CTHRC1) hi fibroblasts and have a synergistic effect in the progress of fibrosis 59 .

A new group of epithelial cells with high expression of CFTR, named ionocytes, was found in airway epithelium 60 . One of the most important functions of CFTR is to regulate chloride channels 61 . Therefore, the mutations of CFTR gene of epithelial cells results in chloride channel defects in airway epithelium, initiating the occurrence of cystic fibrosis 62 . Moreover, the lack of CFTR in airway increased Na + channel activity and Na + hyperabsorption, suggesting that CFTR might be involved in Na + transport 61 . The functional change of epithelial cells in the pancreas and liver is also affected by CFTR mutation 63 . In the normal liver, CFTR cooperates with the chloride channel at the top of cholangiocytes to provide a driving force for bile hydration 64 . Impaired CFTR function lead to mucosal hyperplasia and obstruction of the bile duct. Subsequent bile salt accumulation contributed to hepatocyte damage, inflammation, and fibrosis in the portal vein 64 , 65 .

Endothelial cell

Endothelial cells are main components of blood vessels. Damage to endothelial cells cause abnormal substances exchange between blood and tissues, resulting in metabolic disorders. Furthermore, in fibrotic tissues, abnormal angiogenesis may be induced due to the massive proliferation of fibroblasts requiring more blood nutrients. Studies showed that endothelial cells of different fibrotic tissues may also have specific functions. Two new endothelial cell subtypes, plasmalemma vesicle associated protein (PLVAP) + endothelial cells and atypical chemokine receptor 1 (ACKR1) + endothelial cells, were found in liver tissues of patients with liver cirrhosis and could promote the migration of leukocyte 48 . In lung tissues, five endothelial cell groups were identified by single-cell sequencing, including capillary endothelial cells A and B, venous endothelial cells, and arterial endothelial cells. The fifth kind of endothelial cells recognized by high expression of Collagen 15a1 (COL15A1) gene, located in the bronchioles and fibrous foci, was involved in the production of extracellular matrix 47 .

Immune cells

Abnormality of immune system might be an early event of fibrosis 66 . Immunocytes, such as T lymphocytes, macrophages, dendritic cells, granulocytes, and mast cells, are involved in the fibrosis progress 49 , 67 – 70 . These activated immune cells highly express factors that regulate inflammation and fibrosis, promoting the activation of fibroblasts. T lymphocytes, including CD4 + T cells, CD8 + T cells, and CD8 + effector cells, were increased in IPF patients 71 . The interferon-γ signal transduction in T lymphocytes in IPF was significantly changed 71 , while interleukin (IL) -6 signal in T lymphocytes was mainly up-regulated in patients with systemic sclerosis 67 . In liver tissues, the expression of cytotoxic T cells increased and the inactivation of CD4 + T cells could induce fibrosis 72 .

Macrophages are key cells that mediate inflammation and fibrosis in fibrotic diseases. Seven macrophage subsets were identified in the tissues of patients with liver cirrhosis, including Kupffer cells (resident macrophages in liver) and CD9 + triggering receptor expressed on myeloid cells 2 (TREM2) + macrophages. Pseudo-time sequence analysis showed that TREM2 + CD9 + macrophages were derived from monocytes and increased collagen expression in hepatic stellate cells (HSCs) 48 . In the lung fibrosis, 18 types of immune cells were found, and the phenotypes of tissue resident macrophages, fibrogenic macrophages and inflammatory macrophages were identified 47 , 54 . Resident macrophages in lung are mainly alveolar macrophages (AMs). AMs adheres closely to alveolar epithelium and are exposed to the outside environment 73 . Inhalable particles and other factors directly led to the death of AMs 74 . Activated AMs secreted inflammatory mediators to activate the inflammatory response, and elevated pro-fibrotic factors expression to promote lung fibrosis 75 , 76 . The sialic acid binding Ig-like lectin F (SiglecF) + C-X3-C motif chemokine receptor 1 (CX3CR1) + macrophages were also identified in pulmonary fibrosis mouse model, which were adjacent to fibroblasts and promoted fibrosis by releasing PDGFs to drive the proliferation and activation of fibroblasts 77 .

Fibroblasts

Differentiation of fibroblasts to myofibroblasts with secretory, contractile, and extracellular matrix-producing properties is a key cellular event in many fibrotic conditions. Single-cell sequencing has demonstrated that myofibroblasts have different gene expression profiles with dynamic changes in fibrosis of different organs 78 , 79 . In lung tissue, the differentiation pathways of fibroblasts differ between normal and fibrotic pathological states. Mesenchymal progenitor cells differentiate into lipofibroblasts and COL14A1 + matrix fibroblasts, and the latter then differentiate into myofibroblasts and COL13A1 + matrix fibroblasts. In lung fibrosis, mesenchymal progenitors differentiate into lipofibroblasts, PDGFRβ hi subtypes, COL14A1 + matrix fibroblasts, myofibroblasts, and COL13A1 + matrix fibroblasts 80 . The dominant cell type of fibroblasts in liver are HSCs, which are characterized by their star-like morphology. The differentiation of HSCs may undergo four processes: loss of quiescent properties, promoting inflammation, migration, and ECM production 50 .

Increasing number and activation of myofibroblasts induced by immune cells, EMT, and endothelial-mesenchymal transition (EndMT) are considered major contributors to the process of fibrogenesis 81 , 82 . Inhibiting the proliferation and activation of myofibroblasts has been a critical issue for the treatment of most fibrosis. However, in the fibrotic process, myofibroblast cells could obtain apoptosis resistance during differentiation 83 , which hinders the implementation of programmed death mechanisms 8 . Therefore, the therapeutic method for reducing the number of myofibroblasts has limited efficacy. Moreover, the hyper-activation of myofibroblasts is usually a compensatory result of the death of parenchymal cells such as epithelial cells, cardiomyocytes, and endotheliocytes. Therefore, it might be a more effective treatment method to decrease the death or modulate the activity of parenchymal cells and other related cells, so as to indirectly inhibit myofibroblast activation.

In liver fibrosis, the interaction mechanism of HSCs with other cells is complex. Maintenance of liver sinusoidal endothelial cells (LSECs) differentiation leads to HSCs quiescence and fibrosis regression in normal liver 84 , 85 . However, in fibrotic process, apoptotic hepatocytes increase the inflammatory response and activate macrophages 86 . Extracellular events from Kupffer cells (liver-resident macrophages), hepatocytes, B lymphocytes, and T lymphocytes further modulate the activation of HSCs 87 , 88 . NK cells could kill activated HSCs via regulating retinoic acid-induced 1/natural killer group 2D (NKG2D) -dependent and TNF-related apoptosis-inducing ligands 89 , 90 . Chronic liver injury leads to continuous HSCs activation, which promotes ECM accumulation and tissue structure remodeling, and then results in progressive liver fibrosis 91 (Fig. 2 ). Fig. 2 The activation of HSCs regulated by other cells in liver fibrosis. Extracellular components from injured hepatocytes, Kupffer cells, macrophages, NK cells, T and B lymphocytes modulate HSCs activation via various cytokines. LSECs inhibit or promote the activation of HSCs in different conditions. NK cells kill activated HSCs in IFNγ and TRAIL-dependent ways. TRAIL, TNF-related apoptosis-inducing ligand

In the lung, acute injury of alveolar epithelial cells can cause the reduction of epithelial cells, the destruction of alveolar structure, and the release of pro-inflammatory mediators, thus activating immune cells. These activated inflammatory cells and injured epithelial cells increase the upregulation of cytokines, including TNF-α, IL-1β, IL-6, and TGF-β 92 – 94 . After the initial inflammatory events, pulmonary fibroblasts are activated into myofibroblasts by upregulating fibrotic cytokines such as PDGFs, FGFs, and vascular endothelial growth factor (VEGFs) 95 – 98 . The transition of epithelial cells by the EMT process could also increase the population of myofibroblasts. Chronic activated myofibroblasts produce ECM components (collagens, fibronectin, proteoglycan), leading to lung fibrosis 12 , 22 , 99 (Fig. 3 ). Fig. 3 The interactions among cells involved in lung fibrosis. Injured alveolar epithelial cells activate macrophages, neutrophils, and eosinophils, resulting in the secretion of cytokines, such as TGF-β, IL-1β, and TNF-α. These cytokines mediate the differentiation of fibroblasts into myofibroblasts and the epithelial-mesenchymal transition, which result in the ECM deposition at the injury site

Important signaling pathways in fibrosis

An overwhelming number of mediators have been implicated in fibrosis, regulating myofibroblast activation, metabolism, inflammation, and ECM cross-linking. This part mainly focus on the important signaling pathways involved in fibrotic diseases based on the research intensity and drug efficacy of drug targets in clinical trials.

Growth factors and associated signaling pathways

The growth factors and associated signaling pathways have been reported to promote fibrosis by regulating fibroblasts activation, epithelial cells apoptosis, EMT, and EndMT. Growth factors mainly include TGF-βs, PDGFs, FGFs, and connective tissue growth factor (CTGF). Pathways, such as phosphatidylinositol 3-kinase (PI3K) / protein kinase B (AKT), JAK/STAT, and WNT/β-catenin, are the common downstream signals of these growth factors involved in fibrosis. The interactions between these signaling pathways in fibrosis are depicted in Fig. 4 . Fig. 4 Interactions between growth factors-associated signaling pathways and a summary of related target drugs. PDGFs binding to PDGFRs activates the JAK/STAT, PI3K/AKT, and RAS/ERK signals. FGFs binding to FGFRs activates PI3K/AKT and RAS/ERK signals. CTGF binding to FGFR2 (promoting FGF2 and FGF4 binding to FGFR2) activates RAS/ERK signaling, and CTGF binding to LRP6 activates WNT/β-catenin signaling. Drugs targeting these signaling pathways are listed. EMT: epithelial-mesenchymal transition

TGF-β signaling pathway

TGF-β activation

TGF-βs are the key cytokines in most fibrosis. There are three isoforms of TGF-βs, namely, TGF-β1, TGF-β2, and TGF-β3. The pro-TGF-β monomer synthesized in ribosome, folds in the lumen of the endoplasmic reticulum (ER) and dimerizes via a disulfide linkage. Then, the latency-associated peptide (LAP) binds to mature TGF-β and attaches to latent TGF-β binding protein (LTBP) 100 . This TGF-β/LAP/LTBP complex binds to the ECM in the extracellular space and inactivates TGF-β 101 . The complex can be cleaved by various proteases to release active TGF-β 102 . Activated TGF-βs bind to TGFβR2 and TGFβR1 100 . Upon ligand binding, phosphorylated TGFβR2 then phosphorylates and activates TGFβR1. Factors, such as epidermal growth factor (EGF), IL-1, and TNF-α promote TGF‑β expression in different types of cells 103 , 104 . Moreover, the precursors of TGF-β contain an arginine-glycine-aspartate (RGD) motif, which can be recognized by integrin αv/β6 105 , 106 , suggesting that the activation of TGF-β gene could be regulated by integrin αv/β6. Partial inhibition of TGF-β with an integrin αv/β6 antibody effectively prevented pulmonary fibrosis in mice without aggravating inflammation 107 , 108 .

Canonical and non-canonical signaling

TGF-βs can regulate fibrosis via both canonical and non-canonical signaling pathways. Smad proteins are the canonical intracellular effector of TGF-β/TGFβR. Activated TGFβR1 subsequently induces phosphorylation of Smad2 and Smad3, which interact with Smad4 and enter the nucleus to activate the expression of target genes 102 . Smad7 is a negative regulator of TGF‑β/Smad signaling 109 (Fig. 5 ). TGF-β could also activate non-canonical (non-Smad) signaling pathways, such as PI3K/AKT, mitogen-activated protein kinase (MAPK) pathways, and JAK/ STAT 110 . Macrophages, epithelial cells, and fibroblasts were the main sources of TGF-β in fibrosis 111 , 112 . TGF-β promotes fibrosis through diverse mechanisms, including activation of resident fibroblasts, promotion of cell apoptosis, and induction of EMT. Fig. 5 Overview of canonical TGF-β/Smad signaling pathway. Various cytokines stimulate the transcipiton of TGF-β, such as PDGFs, TGF-βs, TNF-α, IL-1β, and EGF. Pro-TGF-β is synthesized in the ribosome and endoplasmic reticulum. After dimeration, LAP binds to mature TGF-β and attaches to LTBP, entering the intercellular space through exocytosis. Actived TGF-β is released by proteases, and binds to TGFβR2 and TGFβR1. Phosphorylated TGFβR2 phosphorylates TGFβR1. TGFβR1 subsequently triggers the phosphorylation of Smad2/3, which interact with Smad4 and enter the nucleus to activate the expression of target genes. Smad7 is a negative regulator of TGF-β/Smad signaling. LAP, latency-associated peptide; LTBP, latent TGF-β binding protein

Fibroblast activation induced by TGF-β

Activated TGF-β1/Smad3 signaling pathway promoted the recruitment of fibroblasts to injury sites and mediated fibroblast-to-myofibroblast differentiation, thus stimulating the secretion of ECM components 113 – 115 . Reactive oxygen species (ROS) has been reported to mediate TGF-β-induced activation of fibroblasts. NADPH oxidase (Nox) enzymes are important mediators of electron transport from NADPH to oxygen to form ROS 116 . Once produced, ROS could induce the activation of TGF-β1. Nox4 is a member of Nox enzyme family and its expression could be induced by TGF-β in a variety of cells 117 . TGF-β1 treatment increased the level of Nox4 and alpha-smooth muscle actin (α-SMA), a myofibroblast marker, in primary human cardiac fibroblasts, whereas depletion of Nox4 decreased TGF-β1-stimulated α-SMA expression, indicating that ROS mediated TGF-β1-induced activation of cardiac fibroblasts to myofibroblasts 118 . Recent studies have suggested that TGF-β1-driven activation of fibroblasts might involve metabolic reprogramming in fibroblasts and enhancement of glycolytic pathways 119 .

Cell apoptosis induced by TGF-β

TGF-β1-induced apoptosis is important in various fibrosis and the mechanisms might differ between different cell types. ROS plays a key role in endothelial cell apoptosis induced by TGF-β. TGF-β1 caused ROS-dependent p38 activation, while p38 inhibition decrased TGF-β1-induced apoptosis 120 . TGF-β1 could also induce apoptosis of mesangial cells in kidney via p53 phosphorylation and Bcl-2 Associated protein X (Bax) up-regulation 121 .

EMT regulated by TGF-β

In fibrosis, the most common type of EMT is the type 2 EMT process. Type 2 EMT, mainly caused by inflammation, is closely related to tissue damage repair response and increases myofibroblasts population 122 . TGF-β is a crucial mediator in regulating type 2 EMT process in fibrosis and its interaction with various signals regulates the occurrence of EMT. Oxidative stress induced by TGF-β is an important event in the EMT process. TGF-β increased the level of ROS by upregulating the expression of Nox4, and then activated ERK and mTOR signaling molecules to promote EMT and fibrosis 123 . PI3K/AKT signals also mediated TGF-β-induced EMT 124 .

PDGFs/PDGFRs

PDGFs are stimulators of cell division that are required for cell growth and proliferation. They are disulfide-bonded homodimers and heterodimers composed of five different polypeptide chains (subunits), termed AA, AB, BB, CC, and DD 125 . PDGF ligands bind to PDGFRαα, PDGFRαβ and PDGFRββ 126 . PDGF-A and -C subunits mainly bind to the α chain, B subunit to both α and β chains, and D subunit to the β chain only 127 . Upon ligand binding, PDGFRs phosphorylate and activate downstream signals (RAS/MAPK, PI3K/AKT, and JAK/STAT pathways) 128 .

PDGFs are increased in fibrosis. Macrophages, endothelial cells, and fibroblasts have been identified as the main sources of PDGFs 129 – 132 . Both PDGF-B and PDGF-D were potent factors for HSCs proliferation and migration, therefore potentiating extracellular matrix deposition in liver fibrogenesis 133 , 134 , which could be mediated by PGDFRβ 135 . However, deficiency of PDGF-C failed to inhibit liver fibrosis or functional liver impairment 136 , but alleviated kidney fibrotic changes in experimental murine kidney fibrosis 137 . In addition to kidney and liver, studies demonstrated that PDGFs contributed to the formation of heart and lung fibrosis via stimulating activation of fibroblasts 138 – 140 .

FGFs/FGFRs

There are 18 members of the FGF superfamily, which are divided into 6 groups according to sequence homology and differences in biological properties: aFGF and bFGF; INT2, KGF, FGF10, and FGF22; FGF4, FGF5, and FGF6; FGF8, FGF17, and FGF18; FGF9, FGF16, and FGF20; FGF19, FGF21, and FGF23 141 . FGF receptors (FGFR1-FGFR4) are mainly composed of a transmembrane domain, a cytoplasmic tyrosine kinase domain, and an extracellular immunoglobulin domain (D1-D3) 142 . FGFs induce the dimerization, activation, and autophosphorylation of FGFRs and activate the RAS-extracellular signal-regulated kinase (ERK), PI3K-AKT, and JAK/STAT pathways 143 – 145 . The role of FGFs family in liver fibrosis is not clear. FGF19 deficiency protected mice from liver fibrosis progress in animal models 146 . However, direct stimulation of FGF19 decreased pro-fibrotic and pro-inflammatory cytokines expression on HSCs 147 . FGF21 has attracted much attention due to its important role in liver lipid metabolism 148 , 149 . FGF21 acts in an endocrine, paracrine, and autocrine-like manner via FGFR1-3/β-Klotho (KLB) 150 . FGF21-knockout mice decreased β oxidation and increased the level of free fatty acids in mice fed methionine- and choline-deficient (MCD) diets, promoting lipotoxicity and steatosis 151 . Increasing expression of FGF21 inhibited inflammation in NASH, and synergistically alleviated obesity and insulin resistance 151 , 152 . For pulmonary fibrosis, the FGF family is a therapeutic target that promotes fibroblast proliferation and migration but inhibits myofibroblast differentiation 153 – 156 . Inhibition of FGF/FGFR signaling has achieved reduction of pulmonary fibrosis in IPF 157 .

VEGFs/VEGFRs

The VEGF family has 6 members: VEGF-A, -B, -C, -D, -E, and placental growth factor (PIGF) 158 . VEGFs, which are similar to PDGF family proteins in structure, regulates vasculogenesis, angiogenesis and immunity 159 . VEGF-A is widely studied in regulating angiogenesis during homeostasis and disease 160 . VEGF-A exerts its biological functions by binding to VEGFR1 and VEGFR2 160 . VEGF-A were decreased in IPF patients, and lung-specific overexpression of VEGF-A attenuated the lung injury and fibrosis in lung fibrosis mouse model 161 . However, studies have shown the important role of VEGF in promoting pulmonary fibrosis 162 , 163 . The selective splicing of exons contributes to the existence of various subtypes of VEGF-A, including VEGF-A 121 , VEGF-A 165 , VEGF-A 189 , and VEGF-A 206 , among which VEGF-A 165 is the most abundant isoform in normal tissues 164 , 165 . Most studies on the role of VEGF-A in fibrosis have not clearly identified the subtype of VEGF-A, and the dual role of VEGF-A in fibrosis might be related to its different subtypes 166 .

CTGF signaling pathway

CTGF is a secreted peptide and has been considered as a novel PDGF-related growth factor regulating the proliferation and chemotaxis of fibroblasts 167 . CTGF can combine with other molecules to promote their pro-fibrotic effects, thereby promoting fibrosis. The binding of CTGF with FGFR2 enhanced the binding of FGFR to FGF2 and FGF4, thus activating ERK signaling and promoting proliferation 168 . Additional studies have shown that CTGF could bind to TGF-β1 169 and was required for the pro-fibrotic activity of TGF-β1 170 , 171 . TGF-β-induced endogenous CTGF leads to transcriptional repression of Smad7 via inducing the transcription factor TIEG-1, and by this mechanism, CTGF blocks the inhibitory effect of Smad7, resulting in persistent activation of TGF-β signaling 172 .

PI3K/AKT

PI3Ks can be activated by receptor-coupled tyrosine kinase activity, small RAS-related GTPases, and heterotrimeric G proteins 173 . The common downstream of receptor-mediated PI3K activation is AKT, which can phosphorylate many substrates related to cell proliferation, autophagy, and motility 173 . Activated PI3K/AKT negatively regulates the activity of mammalian target of rapamycin (mTOR) 174 . The PI3K/AKT/mTOR is a pivotal signaling involved in cell proliferation and differentiation 175 , and was activated in fibrotic foci 176 , 177 . The activated PI3K/AKT participated in the TGF-β-induced myofibroblasts activation 178 . PI3K/AKT could also regulate angiogenesis by increasing VEGF/VEGFR signaling 179 and enhanced VEGFA/VEGFR2 signaling in liver fibrosis and angiogenesis 180 , 181 .

JAK/STAT

The JAKs has four members, JAK1, 2, 3, and TYK2 182 . Upon ligand binding, JAKs are activated and subsequently phosphorylate downstream signaling molecules, such as STAT, which in turn migrates to the nucleus regulating targeted gene expression 183 , 184 . STAT has seven subtypes: STAT1, 2, 3, 4, 5 A, 5B, and 6 185 , 186 . JAK signal-mediated transduction depends on the activation of PI3K/AKT/mTOR signaling 187 , 188 . Inhibition of PI3K/AKT/mTOR enhanced the effect of JAK2 inhibitors on primary human myeloproliferative neoplasm cells 189 . JAK/STAT could also be regulated by PDGFs. JAK2 and STAT3 was upregulated in left atrial and left ventricular fibroblasts treated with PDGF-AB 190 . Inhibition of JAK2 and STAT3 reversed PDGF-AB-induced collagen production in fibroblasts, suggesting that JAK2/STAT3 signaling was involved in PDGF-AB-induced fibrosis 190 . Furthermore, the activation of JAK/STAT signaling is required for TGF-β-mediated CTGF production in primary mouse HSCs 191 . JAK/STAT signals together with TGF-β1/Smad signals promote the EMT process in liver fibrosis 192 .

WNT/β-catenin

β-catenin is a transcription factor and its expression is mainly regulated by WNT proteins 193 , 194 . WNT/β-catenin activate and synergize with TGF-β1 to mediate the activation of myofibroblasts in lung fibrosis 195 , 196 . WNT/β-catenin signal was upregulated in TGF-β stimulated human lung fibroblasts 197 , 198 . Blocking β-catenin induced by TGF-β in vivo and in vitro can alleviate BLM-induced lung fibrosis 199 . In liver fibrosis, WNT/β-catenin also regulated the vimentin, collagen 1, and fibronectin in HSCs induced by TGF-β 200 . Apart from TGF-β, WNT/β-catenin can be regulated by CTGF via binding to the WNT coreceptor LDL receptor-related protein 6 (LRP6) 201 .

Apoptosis signal-regulating kinase 1 (ASK1) signaling pathway

ASK1 is involved in regulating glucose metabolism and maintaining energy homeostasis, which could activate the p38/cJun NH2-terminal kinase (JNK) signaling pathway 202 . Activation of the JNK signaling cascade suppressed the PPARα and FGF21 pathways 203 . Inhibition of ASK1 reduced insulin resistance, hepatic steatosis, inflammation, and fibrosis 204 , 205 .

Regulation of ECM cross-linking

Lysyl oxidases (LOXs) catalyses the conversion of lysine molecules to highly reactive aldehydes and enhances ECM (primarily collagen and elastin) cross-linking 206 , 207 . LOX family includes lysyl oxidase (LOX) and four lysyl oxidase-like proteins (LOXL1-4) 208 – 210 . The interaction of LOXs with TGF-β mediates the pro-fibrotic effect of LOXs in fibrosis. LOXL1 was required for TGF-β1 induced HSCs activation in liver fibrosis 211 . LOXL1 deficiency protected against TGF-β1-activated fibrosis and decreased the expression of fibrotic genes in vivo 212 . Silencing LOXL2 decreased mouse lung fibroblast proliferation and the levels of collagen 1α1 (COL1A1) via inhibition of TGF-β1/Smad2/3 213 .

Regulation of metabolism and inflammation

Alterations in metabolism can regulate the activation of inflammation-related pathways in epithelial cells, immune cells, and fibroblasts. The interactions between metabolism- and inflammation-related pathways modulate myofibroblasts activation. Signaling molecules that regulate metabolism may provide an interesting avenue for slowing the progression of fibrosis. As most of these signaling pathways regulating metabolism and inflammation are essential for NASH develpoment, the interactions between these signaling pathways in NASH are shown in Fig. 6 . Fig. 6 Molecular signaling pathways of NASH and a summary of related target drugs. FFA, free fatty acid; TG, triglycerides

Peroxisome proliferator-activated receptors (PPARs) signaling pathway

PPARs are the nuclear receptors dependent on ligand binding 214 and activate targeted genes related to lipid and glucose metabolism and adipogenesis 215 , 216 . There are three PPARs: PPARα, PPARγ, and PPARβ (also called δ) 217 , 218 . PPARα is most expressed in brown adipose tissue and liver 219 . The correlation of PPARs with liver fibrosis, especially NASH, is well-elaborated. PPARα is important for fatty acid metabolism 220 . Increased oxidative stress and hepatocyte apoptosis with higher NASH scores were observed in Pparα-null mice fed a high-fat diet 221 . Treatment with PPARα ligands attenuated liver fibrosis in rat thioacetamide models of liver cirrhosis 222 . Fasting-induced PPARα −/− mice showed low levels of FGF21, whereas FGF21 reduced hepatic triglycerides and cholesterol esters only in WT mice, suggesting that the effect of FGF21 on lipid metabolism might be partially dependent on PPARα 223 .

The function of PPARγ in NASH is more dependent on its role in inflammation. PPARγ activation inhibited inflammatory responses by inactivating nuclear factor-κB (NF-κB) signaling 224 and reducing TNF-α and IL-1β expression in monocytes and macrophages 225 . Dual activation of PPARγ and PPARα has a favourable effect in ameliorating NASH by reducing inflammation, steatosis, and fibrosis 226 , 227 . PPAR-α and PPAR-γ activators have achieved efficacy in cardiac fibrosis 228 , renal fibrosis 229 and pulmonary fibrosis 230 animal models.

PPARβ/δ is mainly expressed in hepatocytes, Kupffer cells, and HSCs in liver 231 , 232 . PPARβ/δ-null mice exhibited aggravated hepatoxicity in carbon tetrachloride (CCl 4 )-treated mice 233 . However, the contraditory effects of PPARβ/δ agonists on HSCs proliferation and liver fibrosis hindered PPARβ/δ agonists from entering clinical trials 234 – 236 , which might be due to discrepancies in the ligands, dosage, and in vivo pharmacological properties of compounds.

Farnesoid X receptor (FXR) signaling pathway

FXR, as a nuclear receptor mainly located in enterohepatic tissues, can be activated by bile acids and regulate lipid and glucose metabolism 237 – 239 . FXR forms a heterodimer with the 9-cis-retinoic acid receptor and binds to farnesoid X response elements (FXREs), thus regulating target gene expression 240 . The roles of FXR vary in different organs. FXR expression was upregulated in lung fibrosis, and inhibition of FXR inhibited the bile acid-induced EMT and activation of lung fibroblasts 241 . However, FXR was reported to exert anti-fibrotic effect on kidney fibrosis and liver fibrosis. Treatment with FXR-activating ligand ameliorated triglyceride accumulation, improved proteinuria, and decreased ECM deposition in kidney disease experimental models 242 . FXR activation also protected hepatocytes from liver injury by inhibiting the activation of the NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) inflammasome 243 . The interaction of FXR with other molecules is involved in bile acids circulation and plays an important role in NASH 244 . PPARα activation was required for the mRNA expression of FXR in the liver of fasted mice 245 . FXR directly regulated the expression of FGF19, thereby regulating hepatic protein and glycogen metabolism 246 , 247 . FXR/FGF19 axis increased FGF21 secretion 248 , 249 . FXR might also directly activate the expression of FGF21 by interacting with the FXRE in the 5’-flanking region of the FGF21 gene 248 .

Toll-like receptor 4 (TLR4) signaling pathway

TLR4, a member of the TLR family, functions as a crucial regulator in the immune system and inflammatory response. Fibroblast-specific deletion of TLR4 protected from mice lung and skin fibrosis 250 . In liver fibrosis, HSCs are the main effector cells of TLR4. TLR4 could sensitize HSCs to TGF-β stimulation and promote the activation of Kupffer cells, regulating hepatitis and liver fibrosis 251 . Activation of the TLR4/NF-κB signaling pathway induced hepatic inflammation 252 , 253 . However, TLR4 is an important receptor for AT2 proliferation and deletion of TLR4 in surfactant-protein-C-positive AT2 cells leads to impaired renewal capacity, severe fibrosis and mortality in IPF 254 .

GIP/GIPR and GLP-1/GLP-1R

Gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are the two major incretin hormones produced by the intestine that regulate insulin and glucagon secretion and food ingestion 255 . GIP is secreted by K cells in the upper part of the small intestine, while GLP-1 is mainly released by intestinal endocrine cells 256 – 258 . GIP exerts biological functions via binding to its receptor GIPR 259 , 260 and was related to the activation of macrophages 261 , 262 . GLP-1 is expressed in various cells and binds to GLP-1R 263 . GLP-1 could downregulate collagen expression and TGF-β1 expression via regulating FGF21 in NASH mouse models 264 , 265 and activating AMP-activated protein kinase (AMPK) in diabetic lung fibrosis 266 . Combined treatment with GLP-1R and GIPR agonists improved NASH steatosis, lobular inflammation, hepatocyte ballooning, and fibrosis 267 .

Anti-fibrotic drugs and clinical trials

Numerous small molecules or compounds are currently in clinical trials for fibrosis. Published clinical data on these compounds were listed in Table 1 , and we categorized these drugs by targets and then ranked each target drug by clinical trial grade (marketed, phase 3, phase 2, and phase 1). Accordingly, antifibrotic drugs that have published clinical data and are in Phase 2, Phase 3 clinical trials or marketed are summarized in this part based on the ranking results. Table 1 Drug targets and NCT number of clinical trials Target Drug Name Conditions Highest Status (phase) NCT Status Sample size TGF-β/TGFβR TGF-βs Pirfendione IPF Marketed NCT00662038 Completed 1058 p38 MAPK, TGFβ1, FGFR1 Hydronidone Liver fibrosis III NCT05115942 Recruiting 248 TGFβR1 HEC-585 IPF II NCT05060822 Recruiting 270 αV/β1, αV/β6 PLN-74809 IPF II NCT04396756 Recruiting 112 αV/β6, TGF-β BG00011 IPF II NCT03573505 Terminated 109 αV/β1, αV/β3, αV/β6 IDL-2965 IPF I NCT03949530 Terminated 6 TGF-β1 TRK-250 IPF I NCT03727802 Completed 34 TGF-βs Luspatercept Myelofibrosis III NCT04717414 Recruiting 309 TGF-β, BMPRII Sotatercept Myelofibrosis II NCT01712308 Completed 63 TGF-β1 and TGF-β3 AVID200 Myelofibrosis I NCT03895112 Active, not recruiting 22 FGF FGF21 BIO89-100 NASH II NCT04048135 Active, not recruiting 101 FGF21 Efruxifermin NASH II NCT03976401 Completed 110 FGF21 Pegbelfermin NASH II NCT02413372 Completed 184 FGF19 Aldafermin NASH II NCT03912532 Completed 171 RTKs PDGFRs, FGFRs, VEGFRs Nintedanib IPF Marketed NCT02598193 Completed 89 PDGFRα, β, FGFR1-4, and VEGFR1-3 ZSP1603 IPF II NCT05119972 Recruiting 36 β-Klotho/FGFR1c receptor complex MK-3655 NASH II NCT04583423 Recruiting 328 CTGF CTGF Pamrevlumab IPF III NCT03955146 Recruiting 340 PI3K PI3Kδ Parsaclisib Myelofibrosis III NCT04551053 Recruiting 212 PI3K/mTOR Omipalisib IPF I NCT01725139 Completed 17 PI3K/mTOR HEC-68498 IPF I NCT03502902 Completed 55 PI3K p110α/β/δ/γ Buparlisib Myelofibrosis I NCT01730248 Terminated 63 PI3Kδ, CK1-epsilon Umbralisib Myelofibrosis I NCT02493530 Active, not recruiting 60 JAK JAK1/2 Ruxolitinib Myelofibrosis Marketed NCT02386800 Recruiting 356 JAK2, FLT3 Fedratinib Myelofibrosis III NCT03755518 Active, not recruiting 110 JAK1/2, TBK1, ACVR1/ALK2 Momelotinib Myelofibrosis III NCT04173494 Active, not recruiting 195 JAK2, FLT3, IRAK1 Pacritinib Myelofibrosis III NCT03165734 Recruiting 348 JAK1/2/3 Jaktinib Myelofibrosis III NCT04617028 Recruiting 105 JAK1 Itacitinib Myelofibrosis II NCT04640025 Recruiting 100 JAK2 Ilginatinib Myelofibrosis II NCT01423851 Completed 77 WNT/β-catenin WNT SM04646 IPF II NCT03591926 Withdrawn 0 β-catenin PRI-724 liver cirrhosis II NCT03620474 Completed 27 ASK, MAPK ASK1, MAPKKK5 Selonsertib NASH III NCT03053050 Terminated 808 JNK1, MAPK8 CC-90001 NASH II NCT04048876 Terminated 56 MAP3K19 MG-S-2525 IPF I NCT03650075 Completed 81 LOXL LOXL2, LTD4 receptor, PDE3 /4 Epeleuton NAFLD II NCT02941549 Completed 96 LOXL2, LTD4 receptor, PDE3 /4 Tipelukast IPF II NCT02503657 Completed 15 LOXL2 PAT-1251 Myelofibrosis II NCT04054245 Withdrawn 0 LOXL2 PXS-5382A IPF, NASH I NCT04183517 Completed 18 PPAR PPAR α/δ Elafibranor NASH III NCT02704403 Terminated 2157 PPAR α/γ Saroglitazar NASH III NCT04193982 Recruiting 250 PPAR α/δ/γ Lanifibranor NASH III NCT04849728 Recruiting 2000 PPAR α Pemafibrate NASH II NCT03350165 Completed 118 PPARα/δ ZSP0678 NASH I NCT04137055 Completed 104 FXR FXR Obeticholic Acid NASH III NCT02548351 Active, not recruiting 2480 FXR Cilofexor Liver fibrosis, NASH II NCT02854605 Completed 140 FXR Nidufexor NASH II NCT02913105 Terminated 122 FXR TERN-101 NASH II NCT04328077 Completed 101 FXR Vonafexor NASH II NCT03812029 Completed 120 FXR EDP-305 NASH II NCT04378010 Recruiting 336 FXR Tropifexor NASH II NCT04147195 Terminated 41 TLR TLR4 JKB-121 NASH II NCT02442687 Completed 65 TLR4 JKB-122 NASH II NCT04255069 Active, not recruiting 300 GLP/GIP GLP-1 receptor Semaglutide NASH III NCT04822181 Recruiting 1200 GLP-1/GIP receptor Tirzepatide NASH II NCT04166773 Recruiting 196 GLP-1/Glucagon receptor Cotadutide NASH II NCT05364931 Active, not recruiting 1860 GLP-1/GIP/Glucagon HM-15211 NASH II NCT04505436 Recruiting 217 CFTR CFTR Elexacaftor Cystic fibrosis III NCT03525444 Completed 405 CFTR Ivacaftor Cystic fibrosis III NCT01707290 Completed 125 CFTR GLPG1837 Cystic fibrosis II NCT02707562 Completed 26 CFTR FDL169 Cystic fibrosis II NCT02767297 Completed 46 CFTR Olacaftor Cystic fibrosis II NCT02951182 Completed 74 CFTR VX-152 Cystic fibrosis II NCT02951195 Completed 80 CFTR MRT5005 Cystic fibrosis II NCT03375047 Recruiting 40 CFTR GLPG2737 Cystic fibrosis II NCT03474042 Completed 22 CFTR Nesolicaftor Cystic fibrosis II NCT03591094 Completed 40 CFTR VX-121 Cystic fibrosis II NCT03912233 Completed 87 CFTR ABBV-3067 Cystic fibrosis II NCT03969888 Active, not recruiting 189 CFTR ELX-02 Cystic fibrosis II NCT04135495 Recruiting 16 CFTR Eluforsen Cystic fibrosis II NCT02532764 Completed 70 CFTR Dirocaftor Cystic fibrosis II NCT03251092 Completed 179 CFTR FDL176 Cystic fibrosis I NCT03173573 Completed 109 CFTR Posenacaftor Cystic fibrosis I NCT03140527 Completed 171 CFTR GLPG2451 Cystic fibrosis I NCT02788721 Completed 31 HDAC HDAC Panobinostat Myelofibrosis Marketed NCT02386800 Recruiting 356 HDAC Pracinostat Myelofibrosis II NCT01200498 Completed 23 THRβ THRβ Resmetirom NASH III NCT03900429 Recruiting 2000 THRβ VK2809 NASH II NCT04173065 Recruiting 337 CCR CCR2/CCR5 Cenicriviroc NASH III NCT03028740 Terminated 1778 Galectin Galectin-3 Belapectin NASH III NCT04365868 Recruiting 1010 Galectin-3 GB1211 NASH II NCT04607655 withdrawn 0 Galectin-3 GB0139 IPF II NCT03832946 Active, not recruiting 426 MPC MPC Azemiglitazone potassium NASH III NCT03970031 Active, not recruiting 1800 MPC Deuterium-Stabilized (R)-Pioglitazone NASH II NCT04321343 Active, not recruiting 123 SCD SCD-1 Aramchol NASH III NCT04104321 Recruiting 2000 ATX ATX Ziritaxestat IPF III NCT03711162 Terminated 526 FATP5 FATP5 Ursodiol Cystic Fibrosis II NCT00004315 Unkonwn 20 ACC ACC1/2 PF-05221304 NASH II NCT03248882 Completed 305 ACC Firsocostat NASH II NCT03449446 Completed 395 PDE PDEs (mainly PDE2) ZSP1601 NASH II NCT04140123 Completed 37 LOXL2, LTD4 receptor, PDE3 /4 Epeleuton NAFLD II NCT02941549 Completed 96 LOXL2, LTD4 receptor, PDE3 /4 Tipelukast IPF II NCT02503657 Completed 15 PDE 3/4 Ensifentrine Cystic fibrosis II NCT02919995 Completed 10 AMPK AMPK PXL-770 NAFLD II NCT03763877 Completed 121 MMP MMP2, MMP9, VEGF-A ALS-L1023 NASH II NCT04342793 Unknown 60 A3AR A3AR Namodenoson NASH II NCT02927314 Completed 60 FASN FASN TVB-2640 NASH II NCT03938246 Completed 142 Bioidentical testosterone Bioidentical testosterone LPCN 1144 NASH II NCT04134091 Completed 56 Stem cell Stem cell HepaStem NASH II NCT03963921 Completed 23 HSP HSP 47 BMS-986263 NASH II NCT04267393 Recruiting 270 HSP 90 PU-H71 Myelofibrosis I NCT03935555 Recruiting 24 CD CD3 Foralumab NASH II NCT03291249 Withdrawn 0 CD123 Tagraxofusp Myelofibrosis II NCT02268253 Recruiting 130 ileal bile acid transport ileal bile acid transport Elobixibat NASH II NCT04006145 Completed 47 aldosterone receptor aldosterone receptor Apararenone NASH II NCT02923154 Completed 48 GPR GPR-35 RVT1601 IPF II NCT03864328 Terminated 108 GPR-84 GLPG-1205 IPF II NCT03725852 Completed 68 GPR-40, GPR-84 PBI-4050 IPF II NCT02538536 Completed 41 ROCK2 ROCK2 Belumosudil IPF II NCT02688647 Completed 76 BAFFR BAFFR Ianalumab IPF II NCT03287414 Terminated 30 LPA1 LPA1 BMS-986278 IPF II NCT04308681 Recruiting 360 Telomerase Telomerase Imetelstat Myelofibrosis III NCT04576156 Recruiting 320 KHK KHK PF-06835919 NASH II NCT03969719 Completed 164 calpain calpain 1, 2, and 9 BLD-2660 IPF II NCT04244825 Withdrawn 0 P selectin P selectin Crizanlizumab Myelofibrosis II NCT04097821 Recruiting 243 SMO SMO Sonidegib Myelofibrosis II NCT01787552 Completed 50 Bcl-2 Bcl-2 Navitoclax Myelofibrosis II NCT03222609 Active, not recruiting 191 BET family BET family Pelabresib Myelofibrosis II NCT02158858 Recruiting 341 ENaC ENaC BI-1265162 Cystic fibrosis II NCT04059094 Terminated 52 ENaC P-1037 Cystic fibrosis II NCT02343445 Completed 142 ENaC QBW276 Cystic fibrosis II NCT02566044 Completed 16 ENaC IONIS-ENaCRx Cystic fibrosis I NCT03647228 Completed 98 ENaC AZD5634 Cystic fibrosis I NCT02950805 Completed 9 ENaC BI 443651 Cystic fibrosis I NCT02976519 Completed 64 ENaC Idelalisib Myelofibrosis I NCT02436135 Terminated 10 DNase I DNase I AIR DNase Cystic fibrosis II NCT02722122 Unkonwn 15 AA/DHA imbalance AA/DHA imbalance Fenretinide Cystic fibrosis II NCT03265288 Completed 166 Neutrophil elastase Neutrophil Elastase Lonodelestat Cystic fibrosis II NCT03748199 Completed 32 Neutrophil Elastase CHF 6333 Cystic fibrosis I NCT04010799 Completed 68 leukotriene B4 leukotriene B4 Acebilustat Cystic fibrosis II NCT02443688 Completed 200 CDK CDK1, CDK2/E, CDK2/A, CDK5, 7, 9 Seliciclib Cystic fibrosis II NCT02649751 Terminated 49 CDK4/6 Ribociclib Myelofibrosis I NCT02370706 Completed 15 LSD LSD1 Bomedemstat bis-tosylate Myelofibrosis II NCT03136185 Completed 89 MDM2 MDM2 KRT-232 Myelofibrosis III NCT03662126 Recruiting 385 PLK1 PLK1 Rigosertib Myelofibrosis II NCT02730884 Terminated 3 IL-1α IL-1α Bermekimab(MABp1) Systemic Sclerosis II NCT04045743 Active, not recruiting 20 HSD17B13 HSD17B13 ARO-HSD NASH I NCT04202354 Completed 50 MOTS-c MOTS-c CB4211 NAFLD I NCT03998514 Completed 88 IFN-γ IFN-γ Interferon gamma IPF I NCT00563212 Completed 12 Autotaxin Autotaxin BBT-877 IPF I NCT03830125 Completed 88 Glutathione dependent PGD synthase Glutathione dependent PGD synthase ZL-2102 IPF I NCT02397005 Unknown 120 Arginase Arginase CB-280 Cystic fibrosis I NCT04279769 Completed 32 GSNOR GSNOR N-6022 Cystic fibrosis I NCT01746784 Completed 66 Pim kinase inhibitor Pim-1, -2, -3 kinase TP-3654 Myelofibrosis II NCT04176198 Recruiting 60 PRMT PRMT5 PRT-543 Myelofibrosis I NCT03886831 Active, not recruiting 227 AA/DHA ascorbic acid/ docosahexaenoic acid, ACC acetyl-coenzyme A carboxylase, ACVR1 activin A receptor type 1, ALK2 activin receptor-like kinase 2, ATX autotoxin, A3AR A3 adenosine receptor, BET family bromodomain and extra-terminal domain family, BMPRII bone morphogenic protein receptor type II, CCR2 chemokine receptor 2, CCR5 chemokine receptor 5, CDK cyclin-dependent kinase, EnaC epithelial sodium channel, FASN fatty acid synthase, FATP5 fatty acid transport protein 5, FLT3 FMS-like tyrosine kinase 3, GSNOR S-nitrosoglutathione reductase, HDAC histone deacetylase, HSD17B13 17-beta hydroxysteroid dehydrogenase 13, HSP47 heat shock protein 47, IRAK1 Interleukin-1 receptor-associated kinases, KHK ketohexokinase, LSD1 lysine-specific demethylase 1, LTD4 leukotriene D4, MAPKKK5 MEK Kinase5, MDM2 mouse double minute 2, MMP matrix metallopeptidase, MOTS-c mitochondrial open reading frame of the 12S rRNA-c, MPC mitochondrial pyruvate carrier, NASH non-alcoholic steatosis, PDE phosphodiesterase, PLK1 polo-like kinase 1, PRMT5 protein arginine methyltransferase 5, TBK1 TANK-binding kinase 1, THRβ thyroid hormone receptor beta, SCD-1 stearoyl CoA desaturase-1, SMO Smoothened, SP-B surfactant proteins B

Anti-fibrotic drugs targeting TGF-β

Most anti-TGF-β therapeutic drugs fall into five groups 268 , 269 : (1) nucleic acid drugs that blocking TGF-β synthesis. (2) TGF-β receptor kinases inhibitors, which block ATP binding to TGFβR, thus inhibiting Smad2 and Smad3 activation. (3) monoclonal antibodies preventing TGF-β from binding to its receptors. (4) high-affinity ligand traps prevent TGF-β from binding to its receptor. These inhibitors contain TβRII extracellular domains that could prevent TGF-β1 and TGF-β3 binding to TβRII receptors. (5) Some antibodies or molecules inhibiting the TGF-β activation, for example, drugs targeting αv/β integrins. Anti-fibrotic drugs targeting TGF-β now in clinical trials are mainly used in two diseases, IPF and myelofibrosis. Selected drugs targeting TGF-βs are described in detail.

Pirfenidone

Pirfenidone (PFD) is one of two FDA-approved drugs for IPF 270 , which inhibits both the synthesis and activition of TGF-βs 271 . The action mechanism of PFD in IPF has not been fully elaborated. Studies showed that PFD could inhibit the fibroblasts activation, reducing the synthesis of type 1 and type 3 collagen and the deposition of ECM 272 – 275 . Clinical trials demonstrated that PFD reduced lung function decline, decreased mortality, and improved overall survival of IPF patients 276 – 280 . Anorexia, rash, and gastrointestinal disorders are reported to be common side effects of PFD 281 . Based on the effect of PFD on improving inflammation and fibrosis in IPF, clinical studies on PFD for other types of pulmonary fibrosis are in progress. HEC-585 is a pyrimidine compound that is structurally related to PFD. Two phase I clinical trials were carried out to evaluate the safety, tolerability, and pharmacokinetics of HEC-585 in healthy subjects ( NCT04512170 and NCT03092102 ).

Hydronidone

Hydronidone is a derivative of PFD with potential therapeutic efficacy for hepatic fibrosis 282 . The results of an open-label, randomized, dose-escalating study showed that hydronidone was well tolerated and effectively absorbed in healthy Chinese subjects (ChiCTR-ONC-12002899) 282 . Currently, a phase III study on the efficacy of hydronidone in HBV-induced liver fibrosis is in progress.

Luspatercept

Luspatercept is a recombinant fusion protein that binds TGF-β ligands to reduce Smad2/3 signaling. Luspatercept has been evaluated in myelofibrosis-associated anemia with 33 patients received concomitant ruxolitinib. Among transfusion-independent patients, 2 patients who did not receive ruxolitinib (10%) and 3 patients who received ruxolitinib (21%) experienced an increase of hemoglobin about 1.5 g/dL over 12 weeks. In the transfusion dependent cohort, 2 patients who did not receive ruxolitinib and 6 patients who received ruxolitinib were transfusion independent for at least 12 weeks 283

AVID-200

AVID-200 contains soluble, dimerized, Fc-linked TβRII ectodomains and can be a high-affinity ligand trap preventing TGF-β from binding to its receptor. Treatment of myelofibrosis mononuclear cells with AVID-200 increased numbers of progenitor cells with wild type JAK2 but not mutated JAK2V617F 284 . Phase 1 clinical study in 12 myelofibrosis patients with ruxolitinib resistant showed that eight patients with grade 3/4 adverse reactions did not have dose-limiting toxicity and had improved platelet counts, with an average increase of 48% 283 .

Anti-fibrotic drugs targeting RTKs

Nintedanib

Nintedanib is a receptor tyrosine kinase inhibitor (RTKs: FGFRs, VEGFRs, and PDGFRs) that targets growth factor pathways, including FGFRs, VEGFRs, and PDGFRs 285 . In BLM-treated and silica-induced fibrosis mouse models, nintedanib reduced lung inflammation and fibrosis by decreasing total collagen, inflammatory chemokines, and pro-fibrotic factors both in therapeutic and preventive regimens 157 , 286 . Clinical trials have shown that nintedanib decreased the decline in FVC 287 and reduced disease progression in IPF patients 288 – 291 . Nintedanib had acceptable safety and tolerability 292 , 293 , of which nausea and diarrhoea were the common side effects in the treatment of IPF 294 . The combination of PFD and nintedanib might produce synergistic effects and provide new prospects for the treatment of IPF 277 . However, both nintedanib and PFD have some problems such as high liver toxicity, high dosage, and photoallergic reaction, thus their long-term drug tolerance needs to be further determined.

ZSP1603

ZSP1603 (also known as WXFL-152), identified from a series of 4-hydroxyquinoline derivatives, targets VEGFR2, FGFRs, and PDGFRβ 295 . Our previous study showed the ability of ZSP1603 to reduce pulmonary injury, inflammation, and fibrosis in BLM-treated mice and rats 296 . ZSP1603 could inhibit the proliferation of primary human pulmonary fibroblasts (pHPFs) by blocking the PDGFRβ/ERK signaling pathway and decrease the differentiation of pHPFs by reducing TGF-β1, tissue inhibitor of metalloproteinase -1, and COL1A1 296 . The clinical study of ZSP1603 is expected to provide a new choice for IPF therapy.

Anti-fibrotic drugs targeting CTGF

Pamrevlumab

Pamrevlumab is a recombinant antibody that targets CTGF and inactivates its downstream inflammatory signals 170 . In a phase II, randomized, double-blind, placebo-controlled PRAISE trial involving 7 countries, pamrevlumab decreased the decline in FVC and inhibited the disease progression of IPF ( NCT01890265 ) 297 . More therapeutic effects of pamrevlumab is expected to be investigated in phase III clinical trials ( NCT04419558 ).

Anti-fibrotic drugs targeting PI3K

PI3K/AKT palys an important role in fibrotic processes and represents a critical target for the development of novel anti-fibrotic strategies. PI3K/AKT inhibitors are currently in clinical evaluation in IPF and myelofibrosis.

Parsaclisib

Parsaclisib is a potent PI3Kδ inhibitor and exerts antitumour effects in models of B-cell malignancy 298 . Single-dose parsaclisib alone or combination with itraconazole or rifampin achieved safety and toleratility in healthy subjects 299 . Two clinical trials in phase III studies ( NCT04551066 and NCT04551053 ) were launched to test the efficacy and safety of parsaclisib and ruxolitinib in myelofibrosis.

Omipalisib

Omipalisib (GSK-2126458) is a dual inhibitor of PI3K/mTOR. Omipalisib inhibited the proliferation of pHPFs and decreased collagen accumulation induced by TGF-β1 in pHPFs 176 . Omipalisib was well absorbed and reached the lung in a randomized, placebo-controlled, double-blind phase I study in subjects with IPF ( NCT01725139 ) 300 . Diarrhoea was the most commonly reported side effect of omipalisib 300 .

Anti-fibrotic drugs targeting JAKs

Since JAKs are essential for the occurrence and development of myelofibrosis, JAK inhibitors have achieved improvements in quality of life in patients with myelofibrosis. However, most drugs targeting JAK/STAT did not seem to prevent myelofibrosis patients from progressing to acute myeloid leukemia 301 .

Ruxolitinib

Ruxolitinib, a JAK1/JAK2 inhibitor, is approved by the FDA for patients with intermediate- and high-risk myelofibrosis. The effect of ruxolitinib in anemic myelofibrosis patients was evaluated in a phase 2 study ( NCT02966353 ), who received ruxolitinib at 10 mg for the first 12 weeks, followed by escalating doses to 25 mg. During the study, palpable spleen length was reduced at least 50% in 70% patients receiving ruxolitinib, but 11.8% of patients needed platelet transfusion. The results also showed that the platelet counts and hemoglobin level of patients receiving increased dose were similar to those of patients who did not receice a dose increase 302 .

Momelotinib

Momelotinib (also known as CYT387, a JAK1/2 inhibitor) showed favorable therapeutic effects on myelofibrosis in preclinical trials by reducing multiple myeloma proliferation, inducing apoptosis of JAK2-dependent haematopoietic cells, and regulating inflammatory cytokines 303 . In a phase 3 study ( NCT02101268 ), 156 patients with myeloid fibrosis were assigned to receive momelotinib (104) or standard care (52, 89% of whom received ruxolitinib). Encountered with the standard intervention group (6% of patients), 7% of patients in the momelotinib group had at least a 35% reduction in spleen volume. 11% of patients experienced peripheral neuropathy in the momelotinib group, compared with none in the standard intervention group 304 . Moreover, compared with ruxolitinib, the blood transfusion requirements and drug dependence of momelotinib were markedly reduced 305 .

Fedratinib

Fedratinib is a JAK2 inhibitor and has been used in treatment for patients with myeloproliferative neoplasm-associated myelofibrosis 306 . After 24 weeks, patients in the 400 mg fedratinib group had a 47% spleen volume response rate compared with 1% of patients with myelofibrosis in the placebo group. In this study, the two most common adverse reactions in patients taking fedratinib were anemia and diarrhea 307 .

Pacritinib

Pacritinib is an inhibitor of JAK2 and FMS-like tyrosine kinase 3. Pacritinib has good tolerance and clinical activity in myelofibrosis 308 , 309 . Twice daily pacritinib resulted in a significant reduction in spleen volume and improvements in the total symptom score over the best available therapy for myelofibrosis 310 .

Itacitinib

Itacitinib (INCB039110), a selective JAK1 inhibitor, has demonstrated favourable safety and anticancer effects 311 . Itacitinib exerts its anti-inflammatory effects by reducing pro-inflammatory cytokines and regulating the polarization of macrophages 312 . Administration of itacitinib at 200 mg twice daily and 600 mg once daily reduced the total symptom score in patients with myelofibrosis, and decreased the requirement of red blood cell units transfused in patients who needed transfusions during the 12 weeks prior to itacitinib treatment ( NCT01633372 ) 313 .

Anti-fibrotic drugs targeting β-catenin

PRI-724

PRI-724 (also known as ICG-001) is a small molecule drug that modulate β-catenin/CBP transcription 314 , 315 . Preclinical studies demonstrated the efficacy of PRI-724 in decreasing ECM deposition and hepatic inflammation in a mouse model of CCl 4 -induced acute liver injury 315 and a mouse model of HCV-infection 316 . In a dose escalation phase I trial, PRI-724 was well-tolerated in patients with HCV-induced cirrhosis at the dose of 10 or 40 mg/m(2) daily for 12 weeks 317 . However, PRI-724 did not effectively reduce liver fibrosis in patients with HCV- and HBV-induced cirrhosis, either by sequential scoring or by measuring proportional area of collagen for 12 weeks, but significantly improved liver stiffness ( NCT03620474 ) 318 .

Anti-fibrotic drugs targeting ASK-1

Selonsertib

Selonsertib (GS-4997), a small molecule inhibitor of ASK1, showed efficacy in reducing collagen deposition, fibrosis stage, steatosis, and inflammation in a phase 2 study 319 . However, the phase III clinical trial ( NCT03053050 ) of selonsertib was terminated in NASH patients with bridging fibrosis or compensated cirrhosis because its effect in alleviating fibrosis was not obvious 320 .

Anti-fibrotic drugs targeting PPARs

Since PPARs are involved in glucose and lipid metabolism, PPARs ligands are expected to be promising therapeutic agents for NAFLD/NASH. However, PPARα ligands (Clofibrate and Fenofibrate) showed no effect in inflammation and fibrosis in NASH 231 . PPARβ/δ agonist ( GW501516 ) reduced inflammatory cells migration, insulin resistance and lipid levels, and increased ALT concentration in NASH experimental model 321 , but GW501516 has been terminated due to safety concerns. PPARγ agonists alleviated steatosis and inflammation yet with little effect fibrosis, and long time of administration is a major concern 231 . The effect of dual or pan agonists of PPARs in NASH are summarized below.

Elafibranor

The targets of elafibranor (GFT505) are PPARα and PPARδ 322 . Our previous results showed that GFT505 could inhibit steatosis, inflammation, and fibrosis in a NASH mouse model, and reduce the expression of lipid metabolism-, inflammation-, and fibrosis-related signaling molecules 323 . Treatment with 120 mg/d elafibranor for 1 year reduced NASH progression and liver fibrosis stage 324 . However, a phase III study of elafibranor in NASH patients was terminated because it did not achieve the predicted efficacy without safety issues ( NCT02704403 ).

Saroglitazar

Saroglitazar is a novel dual PPARα/γ agonist that regulates glucose metabolism and improve insulin resistance. NAFLD/NASH patients were given placebo or 1 mg, 2 mg, or 4 mg saroglitazar. After the week 16, the ALT changes in the group taking 1 mg, 2 mg and 4 mg saroglitazine were -25.5%, 27.7%, and -45.8%, respectively, while the ALT changes in the group taking placebo were 3.4%. Administration of saroglitazar 4 mg decreased adiponectin, insulin resistance, and triglycerides, and the avarage body weight in patients taking 4 mg saroglitazar increased by 1.5 kg compared with 0.3 kg in placebo group 325 .

Lanifibranor

Lanifibranor (IVA337) is a PPAR α/γ/δ triple activator that can reduce immune cells infiltration and decreased steatosis in NASH experimental models 326 . In a phase 2b study, NASH patients without cirrhosis received placebo or 800 mg or 1200 mg lanifibranor daily for 24 weeks ( NCT03008070 ). Results showed that most biomarkers of lipid, inflammation, and fibrosis were improved in both dose groups of lanifibranor. However, compared with patients receiving 800 mg lanifibranor, those receiving 1200-mg dose of lanifibranor had greater decrease in the SAF (the steatosis, activity, fibrosis) score 327 .

Pemafibrate

Pemafibrate targeting PPARα modulator regulates lipid and glucose metabolism. Preclinical studies have shown that pemafibrate could improve insulin resistance, inhibit hepatocyte ballooning degeneration, decrease the NAFLD score, and reduce myeloid cell recruitment 328 , 329 . Liver stiffness and ALT level were reduced in patients with high-risk NAFLD who received 0.2 mg pemafibrate twice daily for 72 weeks in a phase 2 trial ( NCT03350165 ) 330 .

Anti-fibrotic drugs targeting FXR

FXR has emerged as a promising therapeutic target for NAFLD/NASH due to its diverse functions that modulate bile acid metabolism, inflammation, and immune responses. FXR agonists could be divided into steroidal and nonsterodial, and pruritus is the most common side effect of these targeted drugs.

Obeticholic acid

Obeticholic acid, a steroidal FXR agonist, has been shown to improve NASH symptoms. In a phase 3 trial ( NCT02548351 ), NASH patients were given placebo, or 10 mg or 25 mg of obeticholic acid daily. Improvement in fibrosis was achieved in 23% of patients in the obeticholic acid 25 mg group compared with 18% of patients in the 10-mg obeticholic acid group and 12% of patients in the placebo group. However, there was no difference of NASH resolution endpoint between the three groups ( P = 0.13) 331 . Patients taking obeticholic acid usually stop or reduce their dosage because of severe pruritus.

Cilofexor

Cilofexor (GS-9674) is a potent and selective FXR nonsteroidal agonist which activates FXR in the intestine and does not experience enterohepatic circulation. Twenty-four weeks of cilofexor improved serum bile acids metabolism and decreased hepatic steatosis in patients with NASH, but there was no significant change in fibrosis ( NCT02854605 ) 332 .

EDP-305

EDP-305 is an effective FXR agonist showing little cross reaction with other nuclear receptors. EDP-305 inhibited HSCs activation in vitro and reduced MCD-induced steatohepatitis and liver fibrosis 333 . Liver fat and ALT level were reduced in NASH patients receiving 2.5 mg of EDP-305 compared with placebo group 334 . Pruritus was also one of the most common adverse events of EDP-305 334 .

Tropifexor

Tropifexor is a non-steroidal FXR agonist and significantly reduced steatohepatitis and fibrosis in NASH preclinical model 335 . Tropifexor was well tolerated up to 3000 µg and 100 µg in the single- and multiple-ascending doses (SAD/MAD) studies, respectively 336 , and is currently in phase 2 development for NASH.

Anti-fibrotic drug targeting TLR4

JKB-121

JKB-121 is a nonselective opioid TLR4 antagonist that has been proved to reduce LPS-induced liver inflammation in a MCD-induced model of NAFLD and inhibit the activation of HSCs 337 .

Anti-fibrotic drugs targeting GIP and GLP-1

FXR mainly negatively regulates liver gluconeogenesis, lipogenesis, and steatosis, while GIP and GLP-1 regulates glucose and lipid metabolism by reducing appetite, regulating liver fat content and inflammation. The dual receptor agonist of GIP and GLP-1 has been considered as an important therapeutic target for NASH.

Tirzepatide

Tirzepatide (LY3298176), a dual GIP and GLP-1 receptor agonist, has been used to explore its efficacy in clinical trials for the treatment of NASH, obesity, and type 2 diabetes mellitus (T2DM) 338 , 339 . Treatment with 10 mg of tirzepatide reduced NASH-related biomarkers, such as serum ALT and aspartate aminotransferase (AST), in patients with T2DM ( NCT03131687 ) 338 . A phase III trial investigating tirzepatide in NASH patients is currently in progress ( NCT04166773 ).

Semaglutide

Semaglutide is a GLP-1 receptor agonist and has been approved for T2DM therapy. In a 72-week phase 2 trial, NASH patients with liver fibrosis of stage F1, F2, or F3 received placebo, or semaglutide at 0.1 mg, 0.2 mg, or 0.4 mg. The percentage of patients who achieved NASH improvement without worsening fibrosis was 40%, 36% and 59% in the 0.1 mg semaglutide group, 0.2 mg semaglutide group and 0.4 mg semaglutide group, respectively, and 17% in the placebo group. However, the changes in fibrosis was not statistically significant in the 0.4 mg semaglutide group (43% of the patients) and in the placebo group (33% of the patients, P = 0.48) 340 .

Cotadutide

Cotadutide (MEDI0382) is a dual receptor agonist of GIP and GLP-1 and has shown safety and tolerability 341 . Cotadutide reduced hepatic lipid content, inflammation, steatosis, and NAS score in a mouse model of NASH 342 .

Anti-fibrotic drugs targeting CFTR

Drugs that improve the structure and function of CFTR have good therapeutic prospects in cystic fibrosis. At present, two kinds of drugs with different action mechanisms but complementary therapeutic effects have been developed, namely, CFTR potentiators and CFTR correctors 343 . CFTR potentiators enhance the gating of CFTR at the cell surface to mediate ion transport and are very effective in treating gated mutations 344 . CFTR correctors modify the processing and transportation of CFTR protein in cells, thus increasing the number of functional CFTR on the cell surface 345 .

Ivacaftor and Tezacaftor

Ivacaftor (VX-770) is the first CFTR potentiators approved by the FDA for cystic fibrosis patients with the gated mutation. Tezacaftor is a CFTR corrector approved by the FDA to be utilized in combination with ivacaftor. In a phase 2 clinical study, daily intake of 100 mg tezacaftor and 150 mg ivacaftor every 12 hours was effective in reducing chloride ion concentration in the sweat of cystic fibrosis patients, while increasing the percent predicted FEV1 (ppFEV1) value by 3.75% ( NCT01531673 ) 346 .

Lumacaftor

Lumacaftor (VX-809), a CFTR corrector, is usually used in combination with ivacaftor for the treatment of cystic fibrosis. Lumacaftor increased the trafficking of CFTR protein to the extracellular membrane, while ivacaftor enabled the opening of dysfunctional chloride channels 347 . In 6- to 11-year-old patients with cystic fibrosis, sweat chloride concentration and CFQ-R RD score were improved after lumacaftor/ivacaftor combination therapy, but the FEV1 parameter was not changed ( NCT02514473 ) 348 . However, FEV1 increased in patients with cystic fibrosis aged 12 years or older in a combination therapy with lumacaftor and ivacaft ( NCT01807949 ) 349 .

ABBV-2222

ABBV-2222 (GLPG2222) is a novel and potent CFTR corrector 350 . Oral administration of ABBV-2222 once daily for 29 days in patients with homozygous or heterozygous of F508del CFTR and a gating mutation reduced sweat chloride concentrations in a dose-dependent manner without ppFEV1 improvements ( NCT03119649 and NCT03045523 ) 351 .

Eluforsen

Eluforsen is an antisense oligonucleotide targeting the F508del mutation mRNA region to restore CFTR function 352 . Inhalation of eluforsen by single or multiple doses (up to 50 mg) demonstrated safety and tolerability 353 . In a phase 1b study, cystic fibrosis patients with a FEV1 > 70% in four single ascending dose cohorts and four MAD cohorts received eluforsen three times weekly for 4 weeks. CFQ-R Respiratory Symptom Score was improved in subjects of three groups in the MAD study 353 .

Conclusions

The high mortality and complex pathogenesis of fibrotic diseases pose great challenges in clinical therapy. Various cells and signaling pathways are involved in the progression of fibrosis. Drugs targeting these abnormal pathways are constantly being developed, and most of them demonstrate good anti-fibrotic properties in clinical trials. However, the side effects of these drugs often lead to drug discontinuation. Therefore, reducing adverse effects is also a great challenge for drug development. In addition, due to the complicated interaction of these signaling pathways in fibrosis, multitarget drug regimens would be beneficial for fibrosis therapy. In conclusion, this review provides reference for further mechanism and drug study of fibrosis.

Acknowledgements

This work was supported by the National Science Foundation of China (No. 81773375) and the National Major Scientific and Technological Special Project (No. 2019ZX09201001). The authors thank the Research Center for Prevention and Therapy of Occupational Diseases, West China-PUMC C.C.Chen Institute of Health, Sichuan University.

Author contributions

Y.Y. and J.Y. designed the research. M.Z., M.W., S.Z., and Y.L. searched and analyzed the papers. M.Z. and L.W. wrote the initial manuscript. M.Z. and Y.Y. prepared the figures. A.C.R., L.Z., B.D., T.Y., H.C., and B.Z. critically reviewed and revised the final manuscript. All the authors have read and approved the manuscript.

Competing interests

The authors declare no competing interests.

References

1. Zhao X Targeting metabolic dysregulation for fibrosis therapy Nat. Rev. Drug Disco. 2020 19 57 75 10.1038/s41573-019-0040-5 31548636

2. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet . 396 , 1204–1222 (2020). 10.1016/S0140-6736(20)30925-9 PMC7567026 33069326

3. Shu DY Lovicu FJ Myofibroblast transdifferentiation: The dark force in ocular wound healing and fibrosis Prog. Retin Eye Res 2017 60 44 65 10.1016/j.preteyeres.2017.08.001 28807717 PMC5600870

4. Rockey DC Bell PD Hill JA Fibrosis-a common pathway to organ injury and failure N. Engl. J. Med 2015 372 1138 1149 10.1056/NEJMra1300575 25785971

5. Tomasek JJ Myofibroblasts and mechano-regulation of connective tissue remodelling Nat. Rev. Mol. Cell Biol. 2002 3 349 363 10.1038/nrm809 11988769

6. Desmoulière A Redard M Darby I Gabbiani G Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar Am. J. Pathol. 1995 146 56 66 7856739 PMC1870783

7. Mascharak S Multi-omic analysis reveals divergent molecular events in scarring and regenerative wound healing Cell Stem Cell 2022 29 315 327.e316 10.1016/j.stem.2021.12.011 35077667 PMC8988390

8. Hinz B Lagares D Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases Nat. Rev. Rheumatol. 2020 16 11 31 10.1038/s41584-019-0324-5 31792399 PMC7913072

9. Beyer C Hypoxia. Hypoxia in the pathogenesis of systemic sclerosis Arthritis Res Ther. 2009 11 220 10.1186/ar2598 19473554 PMC2688169

10. Tsou PS Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma Proc. Natl Acad. Sci. USA 2019 116 3695 3702 10.1073/pnas.1813006116 30755532 PMC6397533

11. Nanthakumar CB Dissecting fibrosis: therapeutic insights from the small-molecule toolbox Nat. Rev. Drug Disco. 2015 14 693 720 10.1038/nrd4592 26338155

12. Parola M Pinzani M Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues Mol. Asp. Med 2019 65 37 55 10.1016/j.mam.2018.09.002 30213667

13. Dhar D Baglieri J Kisseleva T Brenner DA Mechanisms of liver fibrosis and its role in liver cancer Exp. Biol. Med (Maywood) 2020 245 96 108 10.1177/1535370219898141 31924111 PMC7016420

14. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet . 392 , 1789–1858 (2018). 10.1016/S0140-6736(18)32279-7 PMC6227754 30496104

15. Asrani SK Devarbhavi H Eaton J Kamath PS Burden of liver diseases in the world J. Hepatol. 2019 70 151 171 10.1016/j.jhep.2018.09.014 30266282

16. Murray CJ Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 2012 380 2197 2223 10.1016/S0140-6736(12)61689-4 23245608

17. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet . 392 , 1736–1788 (2018). 10.1016/S0140-6736(18)32203-7 PMC6227606 30496103

18. Younossi Z Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention Nat. Rev. Gastroenterol. Hepatol. 2018 15 11 20 10.1038/nrgastro.2017.109 28930295

19. Byrne CD Targher G NAFLD: a multisystem disease J. Hepatol. 2015 62 S47 S64 10.1016/j.jhep.2014.12.012 25920090

20. Yu SM Bonventre JV Acute kidney injury and maladaptive tubular repair leading to renal fibrosis Curr. Opin. Nephrol. Hypertens. 2020 29 310 318 10.1097/MNH.0000000000000605 32205583 PMC7363449

21. Pei G Yao Y Yang Q Lymphangiogenesis in kidney and lymph node mediates renal inflammation and fibrosis Sci. Adv. 2019 5 eaaw5075 10.1126/sciadv.aaw5075 31249871 PMC6594767

22. Majo J Klinkhammer BM Boor P Tiniakos D Pathology and natural history of organ fibrosis Curr. Opin. Pharm. 2019 49 82 89 10.1016/j.coph.2019.09.009 31671319

23. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet . 395 , 709–733 (2020). 10.1016/S0140-6736(20)30045-3 PMC7049905 32061315

24. Krenning G Zeisberg EM Kalluri R The origin of fibroblasts and mechanism of cardiac fibrosis J. Cell Physiol. 2010 225 631 637 10.1002/jcp.22322 20635395 PMC3098503

25. Mewton N Assessment of myocardial fibrosis with cardiovascular magnetic resonance J. Am. Coll. Cardiol. 2011 57 891 903 10.1016/j.jacc.2010.11.013 21329834 PMC3081658

26. Nattel S Molecular and Cellular Mechanisms of Atrial Fibrosis in Atrial Fibrillation JACC Clin. Electrophysiol. 2017 3 425 435 10.1016/j.jacep.2017.03.002 29759598

27. Timmis A European Society of Cardiology: Cardiovascular Disease Statistics 2017 Eur. Heart J. 2018 39 508 579 10.1093/eurheartj/ehx628 29190377

28. Zhou M Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013 Lancet 2016 387 251 272 10.1016/S0140-6736(15)00551-6 26510778

29. Wilson MS Wynn TA Pulmonary fibrosis: pathogenesis, etiology and regulation Mucosal Immunol. 2009 2 103 121 10.1038/mi.2008.85 19129758 PMC2675823

30. Lederer DJ Martinez FJ Idiopathic Pulmonary Fibrosis N. Engl. J. Med 2018 378 1811 1823 10.1056/NEJMra1705751 29742380

31. Martinez FJ Idiopathic pulmonary fibrosis Nat. Rev. Dis. Prim. 2017 3 17074 10.1038/nrdp.2017.74 29052582

32. O’Dwyer DN Ashley SL Moore BB Influences of innate immunity, autophagy, and fibroblast activation in the pathogenesis of lung fibrosis Am. J. Physiol. Lung Cell Mol. Physiol. 2016 311 L590 L601 10.1152/ajplung.00221.2016 27474089 PMC5142210

33. Maher TM Global incidence and prevalence of idiopathic pulmonary fibrosis Respir. Res 2021 22 197 10.1186/s12931-021-01791-z 34233665 PMC8261998

34. Borchers AT Chang C Keen CL Gershwin ME Idiopathic pulmonary fibrosis-an epidemiological and pathological review Clin. Rev. Allergy Immunol. 2011 40 117 134 10.1007/s12016-010-8211-5 20838937

35. Esposito DB Idiopathic Pulmonary Fibrosis in United States Automated Claims. Incidence, Prevalence, and Algorithm Validation Am. J. Respir. Crit. Care Med 2015 192 1200 1207 10.1164/rccm.201504-0818OC 26241562

36. Mossman BT Churg A Mechanisms in the pathogenesis of asbestosis and silicosis Am. J. Respir. Crit. Care Med 1998 157 1666 1680 10.1164/ajrccm.157.5.9707141 9603153

37. Mutsaers SE Fibroblast mitogens in bronchoalveolar lavage (BAL) fluid from asbestos-exposed subjects with and without clinical evidence of asbestosis: no evidence for the role of PDGF, TNF-alpha, IGF-1, or IL-1 beta J. Pathol. 1998 185 199 203 10.1002/(SICI)1096-9896(199806)185:2<199::AID-PATH75>3.0.CO;2-R 9713348

38. Cullinan P Reid P Pneumoconiosis Prim. Care Respir. J. 2013 22 249 252 10.4104/pcrj.2013.00055 23708110 PMC6442808

39. Naehrig S Chao CM Naehrlich L Cystic Fibrosis Dtsch Arztebl Int 2017 114 564 574 28855057 10.3238/arztebl.2017.0564 PMC5596161

40. Powers CA Potter EM Wessel HU Lloyd-Still JD Cystic fibrosis in Asian Indians Arch. Pediatr. Adolesc. Med 1996 150 554 555 10.1001/archpedi.1996.02170300108024 8620244

41. Yamashiro Y The estimated incidence of cystic fibrosis in Japan J. Pediatr. Gastroenterol. Nutr. 1997 24 544 547 10.1097/00005176-199705000-00010 9161949

42. Guo X Clinical and genetic characteristics of cystic fibrosis in CHINESE patients: a systemic review of reported cases Orphanet J. Rare Dis. 2018 13 224 10.1186/s13023-018-0968-2 30558651 PMC6296146

43. Schieber M Crispino JD Stein B Myelofibrosis in 2019: moving beyond JAK2 inhibition Blood Cancer J. 2019 9 74 10.1038/s41408-019-0236-2 31511492 PMC6739355

44. Tefferi A Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management Am. J. Hematol. 2014 89 915 925 10.1002/ajh.23703 25124313

45. Hultcrantz M Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study J. Clin. Oncol. 2012 30 2995 3001 10.1200/JCO.2012.42.1925 22802311 PMC3417050

46. Zahr AA Bone marrow fibrosis in myelofibrosis: pathogenesis, prognosis and targeted strategies Haematologica 2016 101 660 671 10.3324/haematol.2015.141283 27252511 PMC5013940

47. Adams TS Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis Sci. Adv. 2020 6 eaba1983 10.1126/sciadv.aba1983 32832599 PMC7439502

48. Ramachandran P Resolving the fibrotic niche of human liver cirrhosis at single-cell level Nature 2019 575 512 518 10.1038/s41586-019-1631-3 31597160 PMC6876711

49. Xue D Expansion of Fcγ Receptor IIIa-Positive Macrophages, Ficolin 1-Positive Monocyte-Derived Dendritic Cells, and Plasmacytoid Dendritic Cells Associated With Severe Skin Disease in Systemic Sclerosis Arthritis Rheumatol. 2022 74 329 341 10.1002/art.41813 34042322 PMC8626521

50. Yang W Single-Cell Transcriptomic Analysis Reveals a Hepatic Stellate Cell-Activation Roadmap and Myofibroblast Origin During Liver Fibrosis in Mice Hepatology 2021 74 2774 2790 10.1002/hep.31987 34089528 PMC8597108

51. Carraro G Transcriptional analysis of cystic fibrosis airways at single-cell resolution reveals altered epithelial cell states and composition Nat. Med 2021 27 806 814 10.1038/s41591-021-01332-7 33958799 PMC9009537

52. Parimon, T. et al. Alveolar Epithelial Type II Cells as Drivers of Lung Fibrosis in Idiopathic Pulmonary Fibrosis. Int. J. Mol. Sci . 21 , 2269 (2020). 10.3390/ijms21072269 PMC7177323 32218238

53. Yao L Paracrine signalling during ZEB1-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in lung fibrosis Cell Death Differ. 2019 26 943 957 10.1038/s41418-018-0175-7 30050057 PMC6252080

54. Reyfman PA Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis Am. J. Respir. Crit. Care Med 2019 199 1517 1536 10.1164/rccm.201712-2410OC 30554520 PMC6580683

55. Xu Y Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis JCI Insight 2016 1 e90558 10.1172/jci.insight.90558 27942595 PMC5135277

56. Barkauskas CE Type 2 alveolar cells are stem cells in adult lung J. Clin. Invest 2013 123 3025 3036 10.1172/JCI68782 23921127 PMC3696553

57. Zacharias WJ Regeneration of the lung alveolus by an evolutionarily conserved epithelial progenitor Nature 2018 555 251 255 10.1038/nature25786 29489752 PMC6020060

58. Zepp JA Distinct Mesenchymal Lineages and Niches Promote Epithelial Self-Renewal and Myofibrogenesis in the Lung Cell 2017 170 1134 1148.e1110 10.1016/j.cell.2017.07.034 28886382 PMC5718193

59. Kathiriya JJ Human alveolar type 2 epithelium transdifferentiates into metaplastic KRT5(+) basal cells Nat. Cell Biol. 2022 24 10 23 10.1038/s41556-021-00809-4 34969962 PMC8761168

60. Montoro DT A revised airway epithelial hierarchy includes CFTR-expressing ionocytes Nature 2018 560 319 324 10.1038/s41586-018-0393-7 30069044 PMC6295155

61. Stutts MJ CFTR as a cAMP-dependent regulator of sodium channels Science 1995 269 847 850 10.1126/science.7543698 7543698

62. Ratjen F Döring G Cystic fibrosis Lancet 2003 361 681 689 10.1016/S0140-6736(03)12567-6 12606185

63. Olivier AK Gibson-Corley KN Meyerholz DK Animal models of gastrointestinal and liver diseases. Animal models of cystic fibrosis: gastrointestinal, pancreatic, and hepatobiliary disease and pathophysiology Am. J. Physiol. Gastrointest. Liver Physiol. 2015 308 G459 G471 10.1152/ajpgi.00146.2014 25591863 PMC4360044

64. Ledder O Cystic fibrosis: an update for clinicians. Part 2: hepatobiliary and pancreatic manifestations J. Gastroenterol. Hepatol. 2014 29 1954 1962 10.1111/jgh.12785 25238538

65. Feranchak AP Sokol RJ Cholangiocyte biology and cystic fibrosis liver disease Semin Liver Dis. 2001 21 471 488 10.1055/s-2001-19030 11745036

66. Frantz, C. et al. IL-2-related regulatory CD4 T-cell deficiency leads to the development of lung fibrosis and vascular remodeling. Arthritis Rheumatol (2022). 10.1002/art.42111 35255201

67. Valenzi E Disparate Interferon Signaling and Shared Aberrant Basaloid Cells in Single-Cell Profiling of Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease Front Immunol. 2021 12 595811 10.3389/fimmu.2021.595811 33859634 PMC8042271

68. Morimoto Y Amphiregulin-Producing Pathogenic Memory T Helper 2 Cells Instruct Eosinophils to Secrete Osteopontin and Facilitate Airway Fibrosis Immunity 2018 49 134 150.e136 10.1016/j.immuni.2018.04.023 29958800

69. Takemura, N. et al. Eosinophil depletion suppresses radiation-induced small intestinal fibrosis. Sci Transl Med . 10 , eaan0333 (2018). 10.1126/scitranslmed.aan0333 29467297

70. Meadows V Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling Hepatology 2021 74 2684 2698 10.1002/hep.32028 34164827 PMC9337218

71. Serezani, A. P. et al. Multi-Platform Single-Cell Analysis Identifies Immune Cell Types Enhanced in Pulmonary Fibrosis. Am. J. Respir. Cell. Mol. Biol. 10.1165/rcmb.2021-0418OC (2022). 10.1165/rcmb.2021-0418OC PMC9273229 35468042

72. Liang Q The T Cell Receptor Immune Repertoire Protects the Liver From Reconsitution Front Immunol. 2020 11 584979 10.3389/fimmu.2020.584979 33391261 PMC7775400

73. Byrne AJ Mathie SA Gregory LG Lloyd CM Pulmonary macrophages: key players in the innate defence of the airways Thorax 2015 70 1189 1196 10.1136/thoraxjnl-2015-207020 26286722

74. Wang X MCPIP1 Regulates Alveolar Macrophage Apoptosis and Pulmonary Fibroblast Activation After in vitro Exposure to Silica Toxicol. Sci. 2016 151 126 138 10.1093/toxsci/kfw029 26865670 PMC4914799

75. Prasse A A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18 Am. J. Respir. Crit. Care Med 2006 173 781 792 10.1164/rccm.200509-1518OC 16415274

76. Zhang W S100a4 Is Secreted by Alternatively Activated Alveolar Macrophages and Promotes Activation of Lung Fibroblasts in Pulmonary Fibrosis Front Immunol. 2018 9 1216 10.3389/fimmu.2018.01216 29910813 PMC5992816

77. Aran D Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage Nat. Immunol. 2019 20 163 172 10.1038/s41590-018-0276-y 30643263 PMC6340744

78. Farbehi, N. et al. Single-cell expression profiling reveals dynamic flux of cardiac stromal, vascular and immune cells in health and injury. Elife . 8 , e43882 (2019). 10.7554/eLife.43882 PMC6459677 30912746

79. Tabib T SFRP2/DPP4 and FMO1/LSP1 Define Major Fibroblast Populations in Human Skin J. Invest Dermatol 2018 138 802 810 10.1016/j.jid.2017.09.045 29080679 PMC7444611

80. Xie T Single-Cell Deconvolution of Fibroblast Heterogeneity in Mouse Pulmonary Fibrosis Cell Rep. 2018 22 3625 3640 10.1016/j.celrep.2018.03.010 29590628 PMC5908225

81. Yuan Q Tan RJ Liu Y Myofibroblast in Kidney Fibrosis: Origin, Activation, and Regulation Adv. Exp. Med Biol. 2019 1165 253 283 10.1007/978-981-13-8871-2_12 31399969

82. Zeisberg EM Endothelial-to-mesenchymal transition contributes to cardiac fibrosis Nat. Med 2007 13 952 961 10.1038/nm1613 17660828

83. Kato K Impaired Myofibroblast Dedifferentiation Contributes to Nonresolving Fibrosis in Aging Am. J. Respir. Cell Mol. Biol. 2020 62 633 644 10.1165/rcmb.2019-0092OC 31962055 PMC7193787

84. Xie G Role of differentiation of liver sinusoidal endothelial cells in progression and regression of hepatic fibrosis in rats Gastroenterology 2012 142 918 927.e916 10.1053/j.gastro.2011.12.017 22178212 PMC3618963

85. Deleve LD Wang X Guo Y Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence Hepatology 2008 48 920 930 10.1002/hep.22351 18613151 PMC2695448

86. Seki E Schwabe RF Hepatic inflammation and fibrosis: functional links and key pathways Hepatology 2015 61 1066 1079 10.1002/hep.27332 25066777 PMC4306641

87. Tsuchida T Friedman SL Mechanisms of hepatic stellate cell activation Nat. Rev. Gastroenterol. Hepatol. 2017 14 397 411 10.1038/nrgastro.2017.38 28487545

88. Mendez-Sanchez N The cellular pathways of liver fibrosis in non-alcoholic steatohepatitis Ann. Transl. Med 2020 8 400 10.21037/atm.2020.02.184 32355844 PMC7186641

89. Radaeva S Natural killer cells ameliorate liver fibrosis by killing activated stellate cells in NKG2D-dependent and tumor necrosis factor-related apoptosis-inducing ligand-dependent manners Gastroenterology 2006 130 435 452 10.1053/j.gastro.2005.10.055 16472598

90. Jeong WI Suppression of innate immunity (natural killer cell/interferon-γ) in the advanced stages of liver fibrosis in mice Hepatology 2011 53 1342 1351 10.1002/hep.24190 21480338 PMC3079530

91. Rosselli M The metabolic syndrome and chronic liver disease Curr. Pharm. Des. 2014 20 5010 5024 10.2174/1381612819666131206111352 24320032

92. Ramachandran P Iredale JP Fallowfield JA Resolution of liver fibrosis: basic mechanisms and clinical relevance Semin Liver Dis. 2015 35 119 131 10.1055/s-0035-1550057 25974898

93. Zhang Y Enhanced IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure J. Immunol. 1993 150 4188 4196 8473757

94. Chen G IL-1β dominates the promucin secretory cytokine profile in cystic fibrosis J. Clin. Invest 2019 129 4433 4450 10.1172/JCI125669 31524632 PMC6763234

95. Frangogiannis NG The inflammatory response in myocardial injury, repair, and remodelling Nat. Rev. Cardiol. 2014 11 255 265 10.1038/nrcardio.2014.28 24663091 PMC4407144

96. Fan D Takawale A Lee J Kassiri Z Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease Fibrogenes. Tissue Repair 2012 5 15 10.1186/1755-1536-5-15 PMC3464725 22943504

97. Kolb M Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis J. Clin. Invest 2001 107 1529 1536 10.1172/JCI12568 11413160 PMC200196

98. Barron L Gharib SA Duffield JS Lung Pericytes and Resident Fibroblasts: Busy Multitaskers Am. J. Pathol. 2016 186 2519 2531 10.1016/j.ajpath.2016.07.004 27555112 PMC5222977

99. Distler JHW Shared and distinct mechanisms of fibrosis Nat. Rev. Rheumatol. 2019 15 705 730 10.1038/s41584-019-0322-7 31712723

100. Tzavlaki, K. & Moustakas, A. TGF-beta Signaling. Biomolecules . 10 , 487 (2020). 10.3390/biom10030487 PMC7175140 32210029

101. Robertson, I. B. & Rifkin, D. B. Regulation of the Bioavailability of TGF-β and TGF-β-Related Proteins. Cold Spring Harb Perspect Biol . 8 , a021907 (2016). 10.1101/cshperspect.a021907 PMC4888822 27252363

102. Meng XM Nikolic-Paterson DJ Lan HY TGF-beta: the master regulator of fibrosis Nat. Rev. Nephrol. 2016 12 325 338 10.1038/nrneph.2016.48 27108839

103. Jakowlew SB Differential regulation of the expression of transforming growth factor-beta mRNAs by growth factors and retinoic acid in chicken embryo chondrocytes, myocytes, and fibroblasts J. Cell Physiol. 1992 150 377 385 10.1002/jcp.1041500222 1734039

104. Villiger PM Lotz M Differential expression of TGF beta isoforms by human articular chondrocytes in response to growth factors J. Cell Physiol. 1992 151 318 325 10.1002/jcp.1041510213 1572906

105. Shi M Latent TGF-beta structure and activation Nature 2011 474 343 349 10.1038/nature10152 21677751 PMC4717672

106. Aluwihare P Mice that lack activity of alphavbeta6- and alphavbeta8-integrins reproduce the abnormalities of Tgfb1- and Tgfb3-null mice J. Cell Sci. 2009 122 227 232 10.1242/jcs.035246 19118215 PMC2714418

107. Horan GS Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation Am. J. Respir. Crit. Care Med 2008 177 56 65 10.1164/rccm.200706-805OC 17916809

108. Koivisto L Bi J Häkkinen L Larjava H Integrin αvβ6: Structure, function and role in health and disease Int J. Biochem Cell Biol. 2018 99 186 196 10.1016/j.biocel.2018.04.013 29678785

109. Yan X Chen YG Smad7: not only a regulator, but also a cross-talk mediator of TGF-beta signalling Biochem J. 2011 434 1 10 10.1042/BJ20101827 21269274

110. Finnson KW Almadani Y Philip A Non-canonical (non-SMAD2/3) TGF-β signaling in fibrosis: Mechanisms and targets Semin Cell Dev. Biol. 2020 101 115 122 10.1016/j.semcdb.2019.11.013 31883994

111. Coker RK Localisation of transforming growth factor beta1 and beta3 mRNA transcripts in normal and fibrotic human lung Thorax 2001 56 549 556 11413354 10.1136/thorax.56.7.549 PMC1746092

112. Cai X CXCL6-EGFR-induced Kupffer cells secrete TGF-β1 promoting hepatic stellate cell activation via the SMAD2/BRD4/C-MYC/EZH2 pathway in liver fibrosis J. Cell Mol. Med 2018 22 5050 5061 10.1111/jcmm.13787 30106235 PMC6156397

113. Thannickal VJ Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase J. Biol. Chem. 2003 278 12384 12389 10.1074/jbc.M208544200 12531888

114. Chanda D Developmental pathways in the pathogenesis of lung fibrosis Mol. Asp. Med 2019 65 56 69 10.1016/j.mam.2018.08.004 PMC6374163 30130563

115. Cheng Q Methyl ferulic acid attenuates liver fibrosis and hepatic stellate cell activation through the TGF-β1/Smad and NOX4/ROS pathways Chem. Biol. Interact. 2019 299 131 139 10.1016/j.cbi.2018.12.006 30543783

116. Magnani F Mattevi A Structure and mechanisms of ROS generation by NADPH oxidases Curr. Opin. Struct. Biol. 2019 59 91 97 10.1016/j.sbi.2019.03.001 31051297

117. Jiménez-Uribe AP Backstage players of fibrosis: NOX4, mTOR, HDAC, and S1P; companions of TGF-β Cell Signal 2021 87 110123 10.1016/j.cellsig.2021.110123 34438016

118. Cucoranu I NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts Circ. Res 2005 97 900 907 10.1161/01.RES.0000187457.24338.3D 16179589

119. Si, M. et al. Inhibition of hyperglycolysis in mesothelial cells prevents peritoneal fibrosis. Sci. Transl. Med . 11 , eaav5341 (2019). 10.1126/scitranslmed.aav5341 31167927

120. Yan F Nox4 and redox signaling mediate TGF-β-induced endothelial cell apoptosis and phenotypic switch Cell Death Dis. 2014 5 e1010 10.1038/cddis.2013.551 24457954 PMC4040700

121. Negulescu O Estradiol reverses TGF-beta1-induced mesangial cell apoptosis by a casein kinase 2-dependent mechanism Kidney Int 2002 62 1989 1998 10.1046/j.1523-1755.2002.00679.x 12427123

122. Marconi, G. D. et al. Epithelial-Mesenchymal Transition (EMT): The Type-2 EMT in Wound Healing, Tissue Regeneration and Organ Fibrosis. Cells . 10 , 1587 (2021). 10.3390/cells10071587 PMC8307661 34201858

123. Kim SJ Activation of ERK1/2-mTORC1-NOX4 mediates TGF-β1-induced epithelial-mesenchymal transition and fibrosis in retinal pigment epithelial cells Biochem Biophys. Res Commun. 2020 529 747 752 10.1016/j.bbrc.2020.06.034 32736702

124. Zhou T Runt-Related Transcription Factor 1 (RUNX1) Promotes TGF-β-Induced Renal Tubular Epithelial-to-Mesenchymal Transition (EMT) and Renal Fibrosis through the PI3K Subunit p110δ EBioMedicine 2018 31 217 225 10.1016/j.ebiom.2018.04.023 29759484 PMC6013935

125. Papadopoulos N Lennartsson J The PDGF/PDGFR pathway as a drug target Mol. Asp. Med 2018 62 75 88 10.1016/j.mam.2017.11.007 29137923

126. Iwayama T Olson LE Involvement of PDGF in fibrosis and scleroderma: recent insights from animal models and potential therapeutic opportunities Curr. Rheumatol. Rep. 2013 15 304 10.1007/s11926-012-0304-0 23307576 PMC5570472

127. Kazlauskas A PDGFs and their receptors Gene 2017 614 1 7 10.1016/j.gene.2017.03.003 28267575 PMC6728141

128. Borkham-Kamphorst E Weiskirchen R The PDGF system and its antagonists in liver fibrosis Cytokine Growth Factor Rev. 2016 28 53 61 10.1016/j.cytogfr.2015.10.002 26547628

129. Martinet Y Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis N. Engl. J. Med 1987 317 202 209 10.1056/NEJM198707233170404 3600711

130. Vanhee D Mechanisms of fibrosis in coal workers’ pneumoconiosis. Increased production of platelet-derived growth factor, insulin-like growth factor type I, and transforming growth factor beta and relationship to disease severity Am. J. Respir. Crit. Care Med 1994 150 1049 1055 10.1164/ajrccm.150.4.7921435 7921435

131. Ying HZ PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review) Mol. Med Rep. 2017 16 7879 7889 10.3892/mmr.2017.7641 28983598 PMC5779870

132. Heldin P Differential expression of platelet-derived growth factor alpha- and beta- receptors on fat-storing cells and endothelial cells of rat liver Exp. Cell Res 1991 193 364 369 10.1016/0014-4827(91)90108-7 1848517

133. Borkham-Kamphorst E PDGF-D signaling in portal myofibroblasts and hepatic stellate cells proves identical to PDGF-B via both PDGF receptor type alpha and beta Cell Signal 2015 27 1305 1314 10.1016/j.cellsig.2015.03.012 25819339

134. Wang X Targeting the PDGF-B/PDGFR-beta Interface with Destruxin A5 to Selectively Block PDGF-BB/PDGFR-betabeta Signaling and Attenuate Liver Fibrosis EBioMedicine 2016 7 146 156 10.1016/j.ebiom.2016.03.042 27322468 PMC4909612

135. Jiang Y Zhao Y He F Wang H Artificial MicroRNA-Mediated Tgfbr2 and Pdgfrb Co-Silencing Ameliorates Carbon Tetrachloride-Induced Hepatic Fibrosis in Mice Hum. Gene Ther. 2019 30 179 196 10.1089/hum.2018.047 30024280

136. Martin IV Platelet-derived growth factor (PDGF)-C neutralization reveals differential roles of PDGF receptors in liver and kidney fibrosis Am. J. Pathol. 2013 182 107 117 10.1016/j.ajpath.2012.09.006 23141925

137. Eitner F PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis J. Am. Soc. Nephrol. 2008 19 281 289 10.1681/ASN.2007030290 18184860 PMC2396746

138. Nishioka Y Azuma M Kishi M Aono Y Targeting platelet-derived growth factor as a therapeutic approach in pulmonary fibrosis J. Med Invest 2013 60 175 183 10.2152/jmi.60.175 24190033

139. Tuuminen R PDGF-A, -C, and -D but not PDGF-B increase TGF-beta1 and chronic rejection in rat cardiac allografts Arterioscler Thromb. Vasc. Biol. 2009 29 691 698 10.1161/ATVBAHA.108.178558 19213942

140. Gallini R PDGF-A and PDGF-B induces cardiac fibrosis in transgenic mice Exp. Cell Res 2016 349 282 290 10.1016/j.yexcr.2016.10.022 27816607

141. Mohammadi M Olsen SK Ibrahimi OA Structural basis for fibroblast growth factor receptor activation Cytokine Growth Factor Rev. 2005 16 107 137 10.1016/j.cytogfr.2005.01.008 15863029

142. Ghedini GC Ronca R Presta M Giacomini A Future applications of FGF/FGFR inhibitors in cancer Expert Rev. Anticancer Ther. 2018 18 861 872 10.1080/14737140.2018.1491795 29936878

143. Bae JH Schlessinger J Asymmetric tyrosine kinase arrangements in activation or autophosphorylation of receptor tyrosine kinases Mol. Cells 2010 29 443 448 10.1007/s10059-010-0080-5 20432069

144. Katoh M Therapeutics Targeting FGF Signaling Network in Human Diseases Trends Pharm. Sci. 2016 37 1081 1096 10.1016/j.tips.2016.10.003 27992319

145. Ornitz DM Itoh N The Fibroblast Growth Factor signaling pathway Wiley Interdiscip. Rev. Dev. Biol. 2015 4 215 266 10.1002/wdev.176 25772309 PMC4393358

146. Uriarte I Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development Int J. Cancer 2015 136 2469 2475 10.1002/ijc.29287 25346390

147. Schumacher JD Direct and Indirect Effects of Fibroblast Growth Factor (FGF) 15 and FGF19 on Liver Fibrosis Development Hepatology 2020 71 670 685 10.1002/hep.30810 31206730 PMC6918008

148. Geng L Lam KSL Xu A The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic Nat. Rev. Endocrinol. 2020 16 654 667 10.1038/s41574-020-0386-0 32764725

149. Lewis JE Ebling FJP Samms RJ Tsintzas K Going Back to the Biology of FGF21: New Insights Trends Endocrinol. Metab. 2019 30 491 504 10.1016/j.tem.2019.05.007 31248786

150. Sonoda, J., Chen, M. Z. & Baruch, A. FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases. Horm Mol Biol Clin Investig . 30 (2017). 10.1515/hmbci-2017-0002 28525362

151. Fisher FM Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets Gastroenterology 2014 147 1073 1083.e1076 10.1053/j.gastro.2014.07.044 25083607 PMC4570569

152. Yin J Enhanced expression and distinctive characterization of a long-acting FGF21 and its potential to alleviate nonalcoholic steatohepatitis Biochimie 2018 151 166 175 10.1016/j.biochi.2018.05.020 29870802

153. Joannes A FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts in vitro Am. J. Physiol. Lung Cell Mol. Physiol. 2016 310 L615 L629 10.1152/ajplung.00185.2015 26773067

154. Shimbori C Fibroblast growth factor-1 attenuates TGF-β1-induced lung fibrosis J. Pathol. 2016 240 197 210 10.1002/path.4768 27425145

155. Koo HY Fibroblast growth factor 2 decreases bleomycin-induced pulmonary fibrosis and inhibits fibroblast collagen production and myofibroblast differentiation J. Pathol. 2018 246 54 66 10.1002/path.5106 29873400 PMC6175645

156. Yang L FGF/FGFR signaling: From lung development to respiratory diseases Cytokine Growth Factor Rev. 2021 62 94 104 10.1016/j.cytogfr.2021.09.002 34593304

157. Wollin L Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis Eur. Respir. J. 2015 45 1434 1445 10.1183/09031936.00174914 25745043 PMC4416110

158. Hu K Olsen BR Vascular endothelial growth factor control mechanisms in skeletal growth and repair Dev. Dyn. 2017 246 227 234 10.1002/dvdy.24463 27750398 PMC5354946

159. Shibuya M VEGF-VEGFR Signals in Health and Disease Biomol. Ther. (Seoul.) 2014 22 1 9 10.4062/biomolther.2013.113 24596615 PMC3936422

160. Apte RS Chen DS Ferrara N VEGF in Signaling and Disease: Beyond Discovery and Development Cell 2019 176 1248 1264 10.1016/j.cell.2019.01.021 30849371 PMC6410740

161. Murray, L. A. et al. Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis. JCI Insight . 2 , e92192 (2017). 10.1172/jci.insight.92192 PMC5621899 28814671

162. Chaudhary NI Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis Eur. Respir. J. 2007 29 976 985 10.1183/09031936.00152106 17301095

163. Farkas L Gauldie J Voelkel NF Kolb M Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors Am. J. Respir. Cell Mol. Biol. 2011 45 1 15 10.1165/rcmb.2010-0365TR 21057104

164. Ferrara N Adamis AP Ten years of anti-vascular endothelial growth factor therapy Nat. Rev. Drug Disco. 2016 15 385 403 10.1038/nrd.2015.17 26775688

165. Barratt, S. L., Flower, V. A., Pauling, J. D. & Millar, A. B. VEGF (Vascular Endothelial Growth Factor) and Fibrotic Lung Disease. Int. J. Mol. Sci . 19 , 1269 (2018). 10.3390/ijms19051269 PMC5983653 29695053

166. Barratt SL Effects of hypoxia and hyperoxia on the differential expression of VEGF-A isoforms and receptors in Idiopathic Pulmonary Fibrosis (IPF) Respir. Res 2018 19 9 10.1186/s12931-017-0711-x 29334947 PMC5769544

167. Lau LF Cell surface receptors for CCN proteins J. Cell Commun. Signal 2016 10 121 127 10.1007/s12079-016-0324-z 27098435 PMC4882306

168. Aoyama E Kubota S Takigawa M CCN2/CTGF binds to fibroblast growth factor receptor 2 and modulates its signaling FEBS Lett. 2012 586 4270 4275 10.1016/j.febslet.2012.10.038 23142580

169. Toda N Mukoyama M Yanagita M Yokoi H CTGF in kidney fibrosis and glomerulonephritis Inflamm. Regen. 2018 38 14 10.1186/s41232-018-0070-0 30123390 PMC6091167

170. Lipson KE Wong C Teng Y Spong S CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis Fibrogenes. Tissue Repair 2012 5 S24 10.1186/1755-1536-5-S1-S24 PMC3368796 23259531

171. Mao L MKL1 mediates TGF-β-induced CTGF transcription to promote renal fibrosis J. Cell Physiol. 2020 235 4790 4803 10.1002/jcp.29356 31637729

172. Wahab NA Weston BS Mason RM Modulation of the TGFbeta/Smad signaling pathway in mesangial cells by CTGF/CCN2 Exp. Cell Res 2005 307 305 314 10.1016/j.yexcr.2005.03.022 15950619

173. Fruman DA The PI3K Pathway in Human Disease Cell 2017 170 605 635 10.1016/j.cell.2017.07.029 28802037 PMC5726441

174. Janku F Yap TA Meric-Bernstam F Targeting the PI3K pathway in cancer: are we making headway? Nat. Rev. Clin. Oncol. 2018 15 273 291 10.1038/nrclinonc.2018.28 29508857

175. Lawrence, J. & Nho, R. The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis. Int J Mol Sci . 19 , E778 (2018). 10.3390/ijms19030778 PMC5877639 29518028

176. Mercer PF Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF Thorax 2016 71 701 711 10.1136/thoraxjnl-2015-207429 27103349 PMC4975851

177. Wu W Yu Jin Pulvis inhibits carbon tetrachloride-induced liver fibrosis by blocking the MAPK and PI3K/Akt signaling pathways Am. J. Transl. Res 2019 11 5998 6006 31632567 PMC6789276

178. Conte E Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms PLoS One 2011 6 e24663 10.1371/journal.pone.0024663 21984893 PMC3184941

179. Chetty C Lakka SS Bhoopathi P Rao JS MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells Int J. Cancer 2010 127 1081 1095 10.1002/ijc.25134 20027628 PMC2891576

180. Wang L Neuropilin-1 aggravates liver cirrhosis by promoting angiogenesis via VEGFR2-dependent PI3K/Akt pathway in hepatic sinusoidal endothelial cells EBioMedicine 2019 43 525 536 10.1016/j.ebiom.2019.04.050 31060904 PMC6558257

181. Yan Z CD147 promotes liver fibrosis progression via VEGF-A/VEGFR2 signalling-mediated cross-talk between hepatocytes and sinusoidal endothelial cells Clin. Sci. (Lond.) 2015 129 699 710 10.1042/CS20140823 26201021

182. Gadina M Janus kinases to jakinibs: from basic insights to clinical practice Rheumatol. (Oxf.) 2019 58 i4 i16 10.1093/rheumatology/key432 PMC6657570 30806710

183. Maruotti N Corrado A Janus kinase inhibitors role in bone remodeling J. Cell Physiol. 2020 235 1915 1920 10.1002/jcp.29149 31486093

184. Leonard WJ O’Shea JJ Jaks and STATs: biological implications Annu Rev. Immunol. 1998 16 293 322 10.1146/annurev.immunol.16.1.293 9597132

185. Villarino AV Kanno Y O’Shea JJ Mechanisms and consequences of Jak-STAT signaling in the immune system Nat. Immunol. 2017 18 374 384 10.1038/ni.3691 28323260 PMC11565648

186. Wang Y Levy DE Comparative evolutionary genomics of the STAT family of transcription factors Jakstat 2012 1 23 33 24058748 10.4161/jkst.19418 PMC3670131

187. Bartalucci N Guglielmelli P Vannucchi AM Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms Clin. Lymphoma Myeloma Leuk. 2013 13 S307 S309 10.1016/j.clml.2013.07.011 24290217

188. Meyer SC Levine RL Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors Clin. Cancer Res 2014 20 2051 2059 10.1158/1078-0432.CCR-13-0279 24583800 PMC3990645

189. Fiskus W Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells Mol. Cancer Ther. 2013 12 577 588 10.1158/1535-7163.MCT-12-0862 23445613

190. Chen Y JAK-STAT signalling and the atrial fibrillation promoting fibrotic substrate Cardiovasc Res 2017 113 310 320 10.1093/cvr/cvx004 28158495 PMC5852635

191. Liu Y Transforming growth factor-β (TGF-β)-mediated connective tissue growth factor (CTGF) expression in hepatic stellate cells requires Stat3 signaling activation J. Biol. Chem. 2013 288 30708 30719 10.1074/jbc.M113.478685 24005672 PMC3798541

192. Yang YZ Magnesium isoglycyrrhizinate ameliorates high fructose-induced liver fibrosis in rat by increasing miR-375-3p to suppress JAK2/STAT3 pathway and TGF-β1/Smad signaling Acta Pharm. Sin. 2019 40 879 894 10.1038/s41401-018-0194-4 PMC6786319 30568253

193. Xu W Kimelman D Mechanistic insights from structural studies of beta-catenin and its binding partners J. Cell Sci. 2007 120 3337 3344 10.1242/jcs.013771 17881495

194. Murillo-Garzón V Kypta R WNT signalling in prostate cancer Nat. Rev. Urol. 2017 14 683 696 10.1038/nrurol.2017.144 28895566

195. Zhou B Interactions between β-catenin and transforming growth factor-β signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (CREB)-binding protein (CBP) J. Biol. Chem. 2012 287 7026 7038 10.1074/jbc.M111.276311 22241478 PMC3293544

196. Newman DR Expression of WNT5A in Idiopathic Pulmonary Fibrosis and Its Control by TGF-beta and WNT7B in Human Lung Fibroblasts J. Histochem Cytochem 2016 64 99 111 10.1369/0022155415617988 26538547 PMC4812680

197. Ng-Blichfeldt JP TGF-β activation impairs fibroblast ability to support adult lung epithelial progenitor cell organoid formation Am. J. Physiol. Lung Cell Mol. Physiol. 2019 317 L14 l28 10.1152/ajplung.00400.2018 30969812

198. Newman DR Expression of WNT5A in Idiopathic Pulmonary Fibrosis and Its Control by TGF-β and WNT7B in Human Lung Fibroblasts J. Histochem Cytochem 2016 64 99 111 10.1369/0022155415617988 26538547 PMC4812680

199. Mackinnon AC Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3 Am. J. Respir. Crit. Care Med 2012 185 537 546 10.1164/rccm.201106-0965OC 22095546 PMC3410728

200. Beljaars L WNT-5A regulates TGF-β-related activities in liver fibrosis Am. J. Physiol. Gastrointest. Liver Physiol. 2017 312 G219 g227 10.1152/ajpgi.00160.2016 28057611

201. Mercurio S Connective-tissue growth factor modulates WNT signalling and interacts with the WNT receptor complex Development 2004 131 2137 2147 10.1242/dev.01045 15105373

202. Lawan A Hepatic mitogen-activated protein kinase phosphatase 1 selectively regulates glucose metabolism and energy homeostasis Mol. Cell Biol. 2015 35 26 40 10.1128/MCB.00503-14 25312648 PMC4295383

203. Vernia S The PPARα-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway Cell Metab. 2014 20 512 525 10.1016/j.cmet.2014.06.010 25043817 PMC4156535

204. Xiang M Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis J. Hepatol. 2016 64 1365 1377 10.1016/j.jhep.2016.02.002 26860405

205. Xie L DKK3 expression in hepatocytes defines susceptibility to liver steatosis and obesity J. Hepatol. 2016 65 113 124 10.1016/j.jhep.2016.03.008 27016281

206. Schmelzer CEH Lysyl oxidase-like 2 (LOXL2)-mediated cross-linking of tropoelastin FASEB J. 2019 33 5468 5481 10.1096/fj.201801860RR 30676771 PMC6629125

207. Siddikuzzaman, Grace VM Guruvayoorappan C Lysyl oxidase: a potential target for cancer therapy Inflammopharmacology 2011 19 117 129 10.1007/s10787-010-0073-1 21107914

208. Vallet SD Ricard-Blum S Lysyl oxidases: from enzyme activity to extracellular matrix cross-links Essays Biochem 2019 63 349 364 10.1042/EBC20180050 31488698

209. Tenti P Vannucci L Lysyl oxidases: linking structures and immunity in the tumor microenvironment Cancer Immunol. Immunother. 2020 69 223 235 10.1007/s00262-019-02404-x 31650200 PMC7000489

210. Trackman PC Lysyl Oxidase Isoforms and Potential Therapeutic Opportunities for Fibrosis and Cancer Expert Opin. Ther. Targets 2016 20 935 945 10.1517/14728222.2016.1151003 26848785 PMC4988797

211. Ma L Knockdown of LOXL1 inhibits TGF-β1-induced proliferation and fibrogenesis of hepatic stellate cells by inhibition of Smad2/3 phosphorylation Biomed. Pharmacother. 2018 107 1728 1735 10.1016/j.biopha.2018.08.156 30257391

212. Bellaye PS Lysyl Oxidase-Like 1 Protein Deficiency Protects Mice from Adenoviral Transforming Growth Factor-β1-induced Pulmonary Fibrosis Am. J. Respir. Cell Mol. Biol. 2018 58 461 470 10.1165/rcmb.2017-0252OC 29115860

213. Wen X LOXL2, a copper-dependent monoamine oxidase, activates lung fibroblasts through the TGF-β/Smad pathway Int J. Mol. Med 2018 42 3530 3541 30320382 10.3892/ijmm.2018.3927

214. Kersten S Desvergne B Wahli W Roles of PPARs in health and disease Nature 2000 405 421 424 10.1038/35013000 10839530

215. Desvergne B Wahli W Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr. Rev. 1999 20 649 688 10529898 10.1210/edrv.20.5.0380

216. Ahmadian M PPARγ signaling and metabolism: the good, the bad and the future Nat. Med 2013 19 557 566 10.1038/nm.3159 23652116 PMC3870016

217. Cheng, H. S. et al. Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. Int. J. Mol. Sci . 20 , 5055 (2019). 10.3390/ijms20205055 PMC6834327 31614690

218. Monsalve FA Pyarasani RD Delgado-Lopez F Moore-Carrasco R Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases Mediators Inflamm. 2013 2013 549627 10.1155/2013/549627 23781121 PMC3678499

219. Dubois V Eeckhoute J Lefebvre P Staels B Distinct but complementary contributions of PPAR isotypes to energy homeostasis J. Clin. Invest 2017 127 1202 1214 10.1172/JCI88894 28368286 PMC5373878

220. Pawlak M Lefebvre P Staels B Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease J. Hepatol. 2015 62 720 733 10.1016/j.jhep.2014.10.039 25450203

221. Abdelmegeed MA PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver J. Nutr. 2011 141 603 610 10.3945/jn.110.135210 21346097 PMC3056578

222. Toyama T PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats Biochem Biophys. Res Commun. 2004 324 697 704 10.1016/j.bbrc.2004.09.110 15474484

223. Montagner A Liver PPARα is crucial for whole-body fatty acid homeostasis and is protective against NAFLD Gut 2016 65 1202 1214 10.1136/gutjnl-2015-310798 26838599 PMC4941147

224. Konstantinopoulos PA NF-kappaB/PPAR gamma and/or AP-1/PPAR gamma ‘on/off’ switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression Int J. Colorectal Dis. 2007 22 57 68 10.1007/s00384-006-0112-y 16506021

225. Bouhlel MA PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties Cell Metab. 2007 6 137 143 10.1016/j.cmet.2007.06.010 17681149

226. Abd El-Haleim EA Bahgat AK Saleh S Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression Eur. J. Pharm. 2016 773 59 70 10.1016/j.ejphar.2016.01.011 26825546

227. Jain MR Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models Liver Int 2018 38 1084 1094 10.1111/liv.13634 29164820 PMC6001453

228. Iglarz M Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension Hypertension 2003 42 737 743 10.1161/01.HYP.0000083511.91817.B1 12860836

229. Kawai T PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta Lab Invest 2009 89 47 58 10.1038/labinvest.2008.104 19002105

230. Kulkarni AA PPAR-γ ligands repress TGFβ-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis PLoS One 2011 6 e15909 10.1371/journal.pone.0015909 21253589 PMC3017065

231. Liss KH Finck BN PPARs and nonalcoholic fatty liver disease Biochimie 2017 136 65 74 10.1016/j.biochi.2016.11.009 27916647 PMC5380579

232. Girroir EE Quantitative expression patterns of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) protein in mice Biochem Biophys. Res Commun. 2008 371 456 461 10.1016/j.bbrc.2008.04.086 18442472 PMC2586836

233. Shan W Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice Hepatology 2008 47 225 235 10.1002/hep.21925 18038451

234. Hellemans K Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells Gastroenterology 2003 124 184 201 10.1053/gast.2003.50015 12512042

235. Kostadinova R GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation Cell Biosci. 2012 2 34 10.1186/2045-3701-2-34 23046570 PMC3519722

236. Iwaisako K Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist Proc. Natl Acad. Sci. USA 2012 109 E1369 E1376 10.1073/pnas.1202464109 22538808 PMC3361396

237. Matsubara T Li F Gonzalez FJ FXR signaling in the enterohepatic system Mol. Cell Endocrinol. 2013 368 17 29 10.1016/j.mce.2012.05.004 22609541 PMC3491147

238. Wang H FXR modulators for enterohepatic and metabolic diseases Expert Opin. Ther. Pat. 2018 28 765 782 10.1080/13543776.2018.1527906 30259754

239. Kim KH Hepatic FXR/SHP axis modulates systemic glucose and fatty acid homeostasis in aged mice Hepatology 2017 66 498 509 10.1002/hep.29199 28378930 PMC8156739

240. Laffitte BA Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor J. Biol. Chem. 2000 275 10638 10647 10.1074/jbc.275.14.10638 10744760

241. Chen B Bile acids induce activation of alveolar epithelial cells and lung fibroblasts through farnesoid X receptor-dependent and independent pathways Respirology 2016 21 1075 1080 10.1111/resp.12815 27185272

242. Wang XX The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria Am. J. Physiol. Ren. Physiol. 2009 297 F1587 F1596 10.1152/ajprenal.00404.2009 PMC2801344 19776172

243. Han CY FXR Inhibits Endoplasmic Reticulum Stress-Induced NLRP3 Inflammasome in Hepatocytes and Ameliorates Liver Injury Cell Rep. 2018 24 2985 2999 10.1016/j.celrep.2018.07.068 30208322

244. Kong B Luyendyk JP Tawfik O Guo GL Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet J. Pharm. Exp. Ther. 2009 328 116 122 10.1124/jpet.108.144600 PMC2685903 18948497

245. Kok T Induction of hepatic ABC transporter expression is part of the PPARalpha-mediated fasting response in the mouse Gastroenterology 2003 124 160 171 10.1053/gast.2003.50007 12512040

246. Holt JA Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis Genes Dev. 2003 17 1581 1591 10.1101/gad.1083503 12815072 PMC196131

247. Kir S FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis Science 2011 331 1621 1624 10.1126/science.1198363 21436455 PMC3076083

248. Cyphert HA Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21 J. Biol. Chem. 2012 287 25123 25138 10.1074/jbc.M112.375907 22661717 PMC3408207

249. Al-Aqil FA Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk Biochim Biophys. Acta Mol. Basis Dis. 2018 1864 2927 2937 10.1016/j.bbadis.2018.06.003 29883717

250. Bhattacharyya, S. et al. TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung. JCI Insight . 3 , e98850 (2018). 10.1172/jci.insight.98850 PMC6124522 29997297

251. Seki E TLR4 enhances TGF-beta signaling and hepatic fibrosis Nat. Med 2007 13 1324 1332 10.1038/nm1663 17952090

252. Das S NADPH Oxidase-Derived Peroxynitrite Drives Inflammation in Mice and Human Nonalcoholic Steatohepatitis via TLR4-Lipid Raft Recruitment Am. J. Pathol. 2015 185 1944 1957 10.1016/j.ajpath.2015.03.024 25989356 PMC4483465

253. Sutter AG Dietary Saturated Fat Promotes Development of Hepatic Inflammation Through Toll-Like Receptor 4 in Mice J. Cell Biochem 2016 117 1613 1621 10.1002/jcb.25453 26600310 PMC6032519

254. Liang J Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice Nat. Med 2016 22 1285 1293 10.1038/nm.4192 27694932 PMC5503150

255. Gasbjerg, L. S. et al. GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. J. Clin. Endocrinol. Metab . 105 , dgz175 (2020). 10.1210/clinem/dgz175 32077470

256. Smith NK Hackett TA Galli A Flynn CR GLP-1: Molecular mechanisms and outcomes of a complex signaling system Neurochem Int 2019 128 94 105 10.1016/j.neuint.2019.04.010 31002893 PMC7081944

257. Baggio LL Drucker DJ Biology of incretins: GLP-1 and GIP Gastroenterology 2007 132 2131 2157 10.1053/j.gastro.2007.03.054 17498508

258. Seino Y Fukushima M Yabe D GIP and GLP-1, the two incretin hormones: Similarities and differences J. Diabetes Investig. 2010 1 8 23 10.1111/j.2040-1124.2010.00022.x 24843404 PMC4020673

259. Gabe MBN Molecular interactions of full-length and truncated GIP peptides with the GIP receptor - A comprehensive review Peptides 2020 125 170224 10.1016/j.peptides.2019.170224 31809770

260. Adriaenssens AE Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake Cell Metab. 2019 30 987 -996.e986 10.1016/j.cmet.2019.07.013 31447324 PMC6838660

261. Kim SJ GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis PLoS One 2012 7 e40156 10.1371/journal.pone.0040156 22802954 PMC3388996

262. Chen S Okahara F Osaki N Shimotoyodome A Increased GIP signaling induces adipose inflammation via a HIF-1α-dependent pathway and impairs insulin sensitivity in mice Am. J. Physiol. Endocrinol. Metab. 2015 308 E414 E425 10.1152/ajpendo.00418.2014 25537494

263. Drucker DJ Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 Cell Metab. 2018 27 740 756 10.1016/j.cmet.2018.03.001 29617641

264. Valdecantos MP Ruiz L Pardo V Castro-Sanchez L Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy Sci. Rep. 2018 8 16461 10.1038/s41598-018-33949-z 30405191 PMC6220318

265. Trevaskis JL Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice Am. J. Physiol. Gastrointest. Liver Physiol. 2012 302 G762 G772 10.1152/ajpgi.00476.2011 22268099

266. Liu J Glucagon-like peptide-1 (GLP-1) improved diabetic lung fibrosis via AMPK and microRNA-27a (miR-27a) Ann. Transl. Med 2021 9 492 10.21037/atm-21-869 33850889 PMC8039657

267. Kannt A Madsen AN Kammermeier C Elvert R Incretin combination therapy for the treatment of non-alcoholic steatohepatitis Diabetes Obes. Metab. 2020 22 1328 1338 10.1111/dom.14035 32196896

268. Derynck R Turley SJ Akhurst RJ TGFβ biology in cancer progression and immunotherapy Nat. Rev. Clin. Oncol. 2021 18 9 34 10.1038/s41571-020-0403-1 32710082 PMC9721352

269. Ong CH TGF-β-induced fibrosis: A review on the underlying mechanism and potential therapeutic strategies Eur. J. Pharm. 2021 911 174510 10.1016/j.ejphar.2021.174510 34560077

270. Neighbors M Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials Lancet Respir. Med 2018 6 615 626 10.1016/S2213-2600(18)30185-1 30072107

271. Antoniu SA Pirfenidone for the treatment of idiopathic pulmonary fibrosis Expert Opin. Investig. Drugs 2006 15 823 828 10.1517/13543784.15.7.823 16787145

272. Molina-Molina M Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells BMC Pulm. Med 2018 18 63 10.1186/s12890-018-0626-4 29703175 PMC5922028

273. Lehmann M Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis Respir. Res 2018 19 175 10.1186/s12931-018-0876-y 30219058 PMC6138909

274. Epstein Shochet G Wollin L Shitrit D Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype Respirology 2018 23 756 763 10.1111/resp.13287 29532550

275. Knüppel L A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly Am. J. Respir. Cell Mol. Biol. 2017 57 77 90 10.1165/rcmb.2016-0217OC 28257580

276. Iwata T A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study) Respir. Res 2016 17 90 10.1186/s12931-016-0398-4 27450274 PMC4957367

277. Vancheri C Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial Am. J. Respir. Crit. Care Med 2018 197 356 363 10.1164/rccm.201706-1301OC 28889759

278. Yoon HY Kim DS Song JW Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis Respiration 2019 97 242 251 10.1159/000492937 30332670

279. Zurkova M Kriegova E Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry Respir. Res 2019 20 16 10.1186/s12931-019-0977-2 30665416 PMC6341650

280. Noble PW Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials Lancet 2011 377 1760 1769 10.1016/S0140-6736(11)60405-4 21571362

281. Barratt SL South-West of England’s Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Front Pharm. 2018 9 1480 10.3389/fphar.2018.01480 PMC6304353 30618768

282. Liu Y Tolerability and Pharmacokinetics of Hydronidone, an Antifibrotic Agent for Hepatic Fibrosis, after Single and Multiple Doses in Healthy Subjects: an Open-Label, Randomized, Dose-Escalating, First-in-Human Study Eur. J. Drug Metab. Pharmacokinet. 2017 42 37 48 10.1007/s13318-015-0316-z 26797810

283. Tremblay, D. & Mascarenhas, J. Next Generation Therapeutics for the Treatment of Myelofibrosis. Cells . 10 , 1034 (2021). 10.3390/cells10051034 PMC8146033 33925695

284. Varricchio, L. et al. TGF-β1 protein trap AVID200 beneficially affects hematopoiesis and bone marrow fibrosis in myelofibrosis. JCI Insight . 6 , 1–8 (2021). 10.1172/jci.insight.145651 PMC8492354 34383713

285. Rivera-Ortega P Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience Ther. Adv. Respir. Dis. 2018 12 1753466618800618 10.1177/1753466618800618 30249169 PMC6156214

286. Wollin L Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis J. Pharm. Exp. Ther. 2014 349 209 220 10.1124/jpet.113.208223 24556663

287. Brown KK Lung function outcomes in the INPULSIS(®) trials of nintedanib in idiopathic pulmonary fibrosis Respir. Med 2019 146 42 48 10.1016/j.rmed.2018.11.012 30665517

288. Richeldi L Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis N. Engl. J. Med 2014 370 2071 2082 10.1056/NEJMoa1402584 24836310

289. Yoon HY Park S Kim DS Song JW Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Respir. Res 2018 19 203 10.1186/s12931-018-0907-8 30340638 PMC6194688

290. Wuyts WA First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value Lung 2016 194 739 743 10.1007/s00408-016-9912-1 27377558 PMC5031742

291. Kolb M Richeldi L Behr J Maher TM Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume Thorax 2017 72 340 346 10.1136/thoraxjnl-2016-208710 27672117 PMC5520269

292. Pereira CAC Baddini-Martinez JA Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil J. Bras. Pneumol. 2019 45 e20180414 10.1590/1806-3713/e20180414 31531619 PMC8653976

293. Crestani B Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON Lancet Respir. Med 2019 7 60 68 10.1016/S2213-2600(18)30339-4 30224318

294. Kato M Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis Sci. Rep. 2019 9 12062 10.1038/s41598-019-48593-4 31427707 PMC6700168

295. Yao Y Design, synthesis and pharmacological evaluation of 4-(3-chloro-4-(3-cyclopropylthioureido)-2-fluorophenoxy)-7-methoxyquinoline-6-carboxamide (WXFL-152): a novel triple angiokinase inhibitor for cancer therapy Acta Pharmaceutica Sin. B 2020 10 1453 1475 10.1016/j.apsb.2020.04.002 PMC7488503 32963943

296. Liu ZW The antifibrotic effect and mechanism of a novel tyrosine kinase inhibitor, ZSP1603, in preclinical models of pulmonary fibrosis Eur. Rev. Med Pharm. Sci. 2020 24 1481 1491 10.26355/eurrev_202002_20207 32096198

297. Richeldi L Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial Lancet Respiratory Med. 2020 8 25 33 10.1016/S2213-2600(19)30262-0 31575509

298. Shin N Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy J. Pharm. Exp. Ther. 2020 374 211 222 10.1124/jpet.120.265538 32345620

299. Li, J. et al. An Open-Label Study to Assess the Effect of Itraconazole and Rifampin on Parsaclisib Pharmacokinetics When Administered Orally in Healthy Participants. J. Clin. Pharmacol. 60 , 1519–1526 (2020). 10.1002/jcph.1653 PMC7586811 32515832

300. Lukey, P. T. et al. A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis. Eur. Respir. J . 53 , 1801992 (2019). 10.1183/13993003.01992-2018 30765508

301. Mylonas E Single-cell analysis based dissection of clonality in myelofibrosis Nat. Commun. 2020 11 73 10.1038/s41467-019-13892-x 31911629 PMC6946829

302. Cervantes F Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study Leukemia 2021 35 3455 3465 10.1038/s41375-021-01261-x 34017073 PMC8632662

303. Tyner JW CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms Blood 2010 115 5232 5240 10.1182/blood-2009-05-223727 20385788 PMC2892953

304. Harrison CN Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial Lancet Haematol. 2018 5 e73 e81 10.1016/S2352-3026(17)30237-5 29275119

305. Mesa RA SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis J. Clin. Oncol. 2017 35 3844 3850 10.1200/JCO.2017.73.4418 28930494 PMC6553796

306. Talpaz M Kiladjian JJ Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis Leukemia 2021 35 1 17 10.1038/s41375-020-0954-2 32647323 PMC7787977

307. Pardanani A Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis Br. J. Haematol. 2021 195 244 248 10.1111/bjh.17727 34331348 PMC9292894

308. Verstovsek S Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies J. Hematol. Oncol. 2016 9 137 10.1186/s13045-016-0367-x 27931243 PMC5146859

309. Komrokji RS Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis Blood 2015 125 2649 2655 10.1182/blood-2013-02-484832 25762180 PMC4490373

310. Mascarenhas J Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial JAMA Oncol. 2018 4 652 659 10.1001/jamaoncol.2017.5818 29522138 PMC5885169

311. Beatty GL A Phase Ib/II Study of the JAK1 Inhibitor, Itacitinib, plus nab-Paclitaxel and Gemcitabine in Advanced Solid Tumors Oncologist 2019 24 14 e10 10.1634/theoncologist.2017-0665 30115734 PMC6324630

312. Lescoat A Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease Biochem Pharm. 2020 178 114103 10.1016/j.bcp.2020.114103 32562787

313. Mascarenhas JO Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis Haematologica 2017 102 327 335 10.3324/haematol.2016.151126 27789678 PMC5286940

314. Eguchi M Nguyen C Lee SC Kahn M ICG-001, a novel small molecule regulator of TCF/beta-catenin transcription Med Chem. 2005 1 467 472 10.2174/1573406054864098 16787331

315. Akcora BO Storm G Bansal R Inhibition of canonical WNT signaling pathway by beta-catenin/CBP inhibitor ICG-001 ameliorates liver fibrosis in vivo through suppression of stromal CXCL12 Biochim Biophys. Acta Mol. Basis Dis. 2018 1864 804 818 10.1016/j.bbadis.2017.12.001 29217140

316. Tokunaga Y Selective inhibitor of Wnt/β-catenin/CBP signaling ameliorates hepatitis C virus-induced liver fibrosis in mouse model Sci. Rep. 2017 7 325 10.1038/s41598-017-00282-w 28336942 PMC5427997

317. Kimura K Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/beta-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial EBioMedicine 2017 23 79 87 10.1016/j.ebiom.2017.08.016 28844410 PMC5605374

318. Kimura K Safety, tolerability, and anti-fibrotic efficacy of the CBP/β-catenin inhibitor PRI-724 in patients with hepatitis C and B virus-induced liver cirrhosis: An investigator-initiated, open-label, non-randomised, multicentre, phase 1/2a study EBioMedicine 2022 80 104069 10.1016/j.ebiom.2022.104069 35605429 PMC9126795

319. Loomba R The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial Hepatology 2018 67 549 559 10.1002/hep.29514 28892558 PMC5814892

320. Harrison SA Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials J. Hepatol. 2020 73 26 39 10.1016/j.jhep.2020.02.027 32147362

321. Li X Treatment with PPARδ agonist alleviates non-alcoholic fatty liver disease by modulating glucose and fatty acid metabolic enzymes in a rat model Int J. Mol. Med 2015 36 767 775 10.3892/ijmm.2015.2270 26133486

322. Westerouen Van Meeteren MJ Drenth JPH Tjwa E Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH) Expert Opin. Investig. Drugs 2020 29 117 123 10.1080/13543784.2020.1668375 31523999

323. Liu L The pharmacodynamic and differential gene expression analysis of PPAR α/δ agonist GFT505 in CDAHFD-induced NASH model PLoS One 2020 15 e0243911 10.1371/journal.pone.0243911 33326461 PMC7743980

324. Ratziu V Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening Gastroenterology 2016 150 1147 1159.e1145 10.1053/j.gastro.2016.01.038 26874076

325. Gawrieh S Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial Hepatology 2021 74 1809 1824 10.1002/hep.31843 33811367

326. Lefere S Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages(☆) J. Hepatol. 2020 73 757 770 10.1016/j.jhep.2020.04.025 32360434

327. Francque SM A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH N. Engl. J. Med 2021 385 1547 1558 10.1056/NEJMoa2036205 34670042

328. Honda Y Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis Sci. Rep. 2017 7 42477 10.1038/srep42477 28195199 PMC5307366

329. Sasaki Y Pemafibrate, a selective PPARα modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content Sci. Rep. 2020 10 7818 10.1038/s41598-020-64902-8 32385406 PMC7210999

330. Nakajima A Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease Aliment Pharm. Ther. 2021 54 1263 1277 10.1111/apt.16596 PMC9292296 34528723

331. Younossi ZM Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Lancet 2019 394 2184 2196 10.1016/S0140-6736(19)33041-7 31813633

332. Patel K Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial Hepatology 2020 72 58 71 10.1002/hep.31205 32115759

333. An P Wei G Huang P A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction Liver Int. 2020 40 1655 1669 10.1111/liv.14490 32329946 PMC7384094

334. Ratziu V EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study J. Hepatol. 2022 76 506 517 10.1016/j.jhep.2021.10.018 34740705

335. Hernandez ED Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis Is Associated With the Antioxidative Gene Expression Profile in Rodents Hepatol. Commun. 2019 3 1085 1097 10.1002/hep4.1368 31388629 PMC6672390

336. Badman MK Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers Clin. Pharm. Drug Dev. 2020 9 395 410 10.1002/cpdd.762 PMC7187203 31823525

337. Sumida Y Yoneda M Current and future pharmacological therapies for NAFLD/NASH J. Gastroenterol. 2018 53 362 376 10.1007/s00535-017-1415-1 29247356 PMC5847174

338. Hartman ML Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes Diabetes Care 2020 43 1352 1355 10.2337/dc19-1892 32291277 PMC7245348

339. Frias JP Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Lancet 2018 392 2180 2193 10.1016/S0140-6736(18)32260-8 30293770

340. Newsome PN A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis N. Engl. J. Med 2021 384 1113 1124 10.1056/NEJMoa2028395 33185364

341. Ambery PD MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study Br. J. Clin. Pharm. 2018 84 2325 2335 10.1111/bcp.13688 PMC6138475 29926478

342. Boland ML Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis Nat. Metab. 2020 2 413 431 10.1038/s42255-020-0209-6 32478287 PMC7258337

343. Goor, F. V., Hadida, S. & Grootenhuis, P. Pharmacological Rescue of Mutant CFTR Function for the Treatment of Cystic Fibrosis . (Ion Channels, 2008).

344. Jih KY Lin WY Sohma Y Hwang TC CFTR potentiators: from bench to bedside Curr. Opin. Pharm. 2017 34 98 104 10.1016/j.coph.2017.09.015 PMC5723237 29073476

345. Rowe SM Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis N. Engl. J. Med 2017 377 2024 2035 10.1056/NEJMoa1709847 29099333 PMC6472479

346. Donaldson SH Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR Am. J. Respir. Crit. Care Med 2018 197 214 224 10.1164/rccm.201704-0717OC 28930490 PMC5768901

347. Connett GJ Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy Drug Des. Devel Ther. 2019 13 2405 2412 10.2147/DDDT.S153719 31409974 PMC6650604

348. Milla CE Lumacaftor/Ivacaftor in Patients Aged 6-11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR Am. J. Respir. Crit. Care Med 2017 195 912 920 10.1164/rccm.201608-1754OC 27805836 PMC5440888

349. Wainwright CE Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR N. Engl. J. Med 2015 373 220 231 10.1056/NEJMoa1409547 25981758 PMC4764353

350. Wang, X. et al. Discovery of 4-[(2R,4R)-4-({[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic Acid (ABBV/GLPG-2222), a Potent Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Corrector for the Treatment of Cystic Fibrosis. J. Med. Chem . 61 , 1436–1449 (2018). 10.1021/acs.jmedchem.7b01339 29251932

351. Bell SC CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials J. Cyst. Fibros. 2019 18 700 707 10.1016/j.jcf.2019.04.014 31056441

352. Kim J Metabolite Profiling of the Antisense Oligonucleotide Eluforsen Using Liquid Chromatography-Mass Spectrometry Mol. Ther. Nucleic Acids 2019 17 714 725 10.1016/j.omtn.2019.07.006 31422288 PMC6704339

353. Drevinek P Antisense oligonucleotide eluforsen is safe and improves respiratory symptoms in F508DEL cystic fibrosis J. Cyst. Fibros. 2020 19 99 107 10.1016/j.jcf.2019.05.014 31182369